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(Glickman and Raveh, 2005; Schmidt et al., 2005). The proteolytic 
component of the proteasome is the 20S core particle, which may 
be associated with several different types of activating particles in 
addition to the 19S regulatory particle, which binds to ubiquitylated 
proteins (Rechsteiner and Hill, 2005). In the 26S proteasome, a 
single 20S particle may associate with one or two 19S particles to 
form a singly- or doubly-capped 26S proteasome. Several studies 
have shown that neuron-speciﬁ  c mechanisms of 26S proteasome 
regulation may underlie synaptic plasticity (DiAntonio and Hicke, 
2004; Bingol and Schuman, 2005; Yi and Ehlers, 2007). A striking 
example is the rapid redistribution of 26S proteasomes into den-
dritic spines following neuronal stimulation (Bingol and Schuman, 
2006). Inside the synapse, proteasome-mediated proteolysis can 
regulate the internalization of glutamate receptors (Patrick et al., 
2003) as well as the abundance of many PSD proteins (Ehlers, 2003; 
Bingol and Schuman, 2004).
It is also likely that proteasome regulation occurs through 
changes in the levels of proteasome-interacting proteins. In mam-
mals, USP14 and Rpn13/UCH37, both deubiquitylating enzymes 
or DUBs, inﬂ  uence substrate degradation through their interac-
tion with the 26S proteasome (Koulich et al., 2008). The spontane-
ous mutation of Usp14 in mice leads to synaptic ubiquitin defects 
and altered short-term synaptic plasticity (Wilson et al., 2002; 
Chen et al., 2009). In addition to 33 different integral subunits, 
mass-spectrometric analysis of gently-puriﬁ  ed proteasomes from 
INTRODUCTION
In eukaryotic cells, most intracellular proteins are degraded by the 
ubiquitin-proteasome system (UPS). In this pathway, polyubiquit-
ylation of a protein marks it for degradation by the 26S proteasome 
(Hershko and Ciechanover, 1998). In neurons, the UPS modulates 
the function and plasticity of synapses in normal and diseased states 
(DiAntonio and Hicke, 2004; Yi and Ehlers, 2007; Tai and Schuman, 
2008). The UPS has been shown to regulate presynaptic vesicle release 
(Willeumier et al., 2006; Yao et al., 2007) and the restructuring of 
the postsynaptic density (PSD) (Ehlers, 2003; Bingol and Schuman, 
2004). In fact, the inhibition of proteasome activity can impair syn-
aptic plasticity (Fonseca et al., 2006; Hou et al., 2006; Karpova et al., 
2006), and certain types of learning in animals (Lopez-Salon et al., 
2001; Lee et al., 2008). Another critical function of the UPS is to pro-
tect neurons by clearing damaged and misfolded proteins (Goldberg, 
2003). Intraneuronal aggregates of misfolded proteins are the hall-
marks of many neurodegenerative disorders, such as α-synuclein 
in Parkinson’s disease and hyperphosphorylated tau in Alzheimer’s 
disease. Frequently, these aggregates contain ubiquitylated proteins 
and proteasomes, and it has often been suggested that impairment 
of the UPS underlies neurodegeneration (Sherman and Goldberg, 
2001; Rubinsztein, 2006; Bedford et al., 2008b).
There is growing evidence that ubiquitylation is not the only 
site of regulation of this pathway and that proteasome composi-
tion, and presumably function, can be regulated in multiple ways 
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non-neuronal tissues and cells has revealed many proteins that 
interact with 26S proteasomes (Wang and Huang, 2008; Besche 
et al., 2009; Scanlon et al., 2009). However, their speciﬁ  c functions 
and mode of regulation are generally unclear.
In particular, there are no published studies about what proteins 
interact substoichiometrically with 26S proteasomes in the brain 
and how they are regulated. Recently, Besche et al. (2009) have 
described an afﬁ  nity puriﬁ  cation method that allows gentle, rapid 
isolation of 26S proteasomes together with associated proteins. This 
approach, which is based upon the high afﬁ  nity of 26S proteasomes 
for the ubiquitin-like (UBL) domain of Rad23B (Schauber et al., 
1998), has revealed various new proteasome-associated proteins, 
among them several ubiquitin ligases and DUBs. In this study, we 
have utilized this newly developed method for purifying 26S pro-
teasomes from the adult rat cortex. We speciﬁ  cally isolated 26S 
proteasomes from biochemically puriﬁ  ed neuronal fractions and 
compared the interacting proteins found in synaptic and cytosolic 
fractions by tandem mass spectrometry. We found that the 26S 
proteasome-interacting proteins differ between the synapse and 
the cytosol, and even more so between the cortex and other tissues. 
Moreover, neuronal activity was found to alter the functional capac-
ity of the UPS. Following the exposure of neurons to N-methyl-
D-aspartate (NMDA), we identiﬁ  ed several novel mechanisms 
that down-regulate the UPS, including the disassembly of 26S 
proteasomes, the degradation of proteasome-associated ubiquitin 
ligases (E3s), and the degradation of 19S regulatory particles in a 
 proteasome-dependent  manner.
MATERIALS AND METHODS
REAGENTS
Antibodies against the following antigens were purchased com-
mercially:  α7 (PW8110), Rpt1 (PW8825), UBE3A (PW0535), 
ubiquitin conjugates (UG9510), PI31 (PW9710) from Biomol/
Enzo (Plymouth Meeting, PA, USA); ECM29 (PA3-035), USP14 
(MA1-57109), PA28α (PA1-960) from Afﬁ  nity  Bioreagents/
Thermo (Rockford, IL, USA); parkin (MAB5512), ubiquitin 
monomer (MAB1510) from Chemicon/Millipore (Billerica, MA, 
USA); PSMD9 (sc-10670), 14-3-3γ (sc-731) from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA); HUWE1 (A300-486A) 
from Bethyl (Montgomery, TX, USA); tubulin β3 (T8860) from 
Sigma (St Louis, MO, USA); KCMF1 (15-288-21213) from Genway 
(San Diego, CA, USA); drebrin (ab12350) and GRASP-1 (ab30576) 
from Abcam (Cambridge, MA, USA). Nonidet P-40 (NP-40) was 
purchased from BDH (Poole, England). Protease inhibitor cocktail 
(complete, EDTA-free) was from Roche (Indianapolis, IN, USA). 
Phosphatase inhibitor (cocktail 2), NMDA, and chloroquine were 
from Sigma. Epoxomicin and clasto-lactacystin β-lactone were 
from Enzo. Tetrodotoxin (TTX), (S)-3,5-dihydroxyphenylglycine 
(DHPG), 2-amino-5-phosphonopentanoic acid (APV), 6-cyano-
7-nitroquinoxaline-2,3-dione (CNQX), and concanamycin A were 
from Tocris (Ellisville, MO, USA).
RECOMBINANT PROTEIN PURIFICATION
GST-UBL and His10-UIM plasmids and their expression in bacteria 
have been previously described (Besche et al., 2009). pDEST-15-
HHR23BUBL plasmid was transformed into BL21AI (Invitrogen) 
according to manufacturer’s instructions. Cells were grown at 
37°C with ampicillin to an OD600 of 0.5 and induced for 3 h with 
1 g/L L-arabinose. Cell pellet from 1 L culture was resuspended in 
100 mL ice-cold phosphate buffered saline (PBS, 10 mM Na2HPO4, 
1.8 mM KH2PO4, 2.7 mL KCl, 137 mM NaCl, pH 7.4) with 2 mM 
DTT, 10 mM MgCl2, 0.2 mg/mL lysozyme and protease inhibitors 
(complete, Roche). The entire puriﬁ  cation procedure was carried 
out at 4°C. Cells were lysed by sonication, and the cell debris was 
removed by centrifugation at 20,000 × g for 30 min. The super-
natant was passed through 0.2-µm ﬁ  lters and supplemented with 
0.2% Triton X-100, followed by incubation with 20 mL of glu-
tathione sepharose for 2 h. The resin was transferred to a gravity-
ﬂ  ow column, and washed several times in PBS with 0.2% Triton 
X-100. GST-UBL was eluted by adding 50 mL of elution buffer 
(75 mM Tris pH 8.8, 150 mM NaCl, 40 mM reduced glutathione), 
and the collected fractions were combined and dialyzed against 
buffer B (25 mM HEPES pH 7.5, 10% glycerol, 5 mM MgCl2 1 mM 
DTT). Small aliquots of 10 mg/mL GST-UBL were frozen in liquid 
nitrogen and stored at −80°C. The ﬁ  nal yield from 1 L culture was 
∼100 mg.
pET26b-S5aUIM2 plasmid was transformed into BL21 (DE3) 
(Promega) according to manufacturer’s instructions. Cells were 
grown at 37°C with kanamycin to an OD600 of 0.8, followed by 
induction with 0.5 mM IPTG for 2 h at 30°C. Pellets from 1-L 
culture (∼20 mg of His10-UIM) were resuspended in 30 mL B-PER 
extraction reagent (Pierce/Thermo) supplemented with 3  mM 
2-mercaptoethanol and DNase I (Sigma). After 15 min of extraction 
at 25°C with mixing, the lysate was cooled to 4°C and centrifuged at 
20,000 × g for 20 min. The supernatant was passed through 0.2-µm 
ﬁ  lters, supplemented with 10 mM imidazole, and incubated with 
10 mL of Ni-NTA for 1 h. The resin was transferred to a gravity-ﬂ  ow 
column and washed ﬁ  rst with a 1:1 mixture of B-PER and wash 
buffer (50 mM Tris pH 7.5, 40 mM imidazole, 300 mM NaCl), and 
then just wash buffer. Twenty milliliters of elution buffer (50 mM 
Tris pH 7.5, 250 mM imidazole, 300 mM NaCl) was added, and 
collected fractions containing His10-UIM were combined and dia-
lyzed against buffer B with 40 mM KCl. Protein concentration was 
compared to bovine serum albumin standards (Pierce/Thermo) 
using two gel-staining methods: Coomassie blue and E-Zinc stain 
(Pierce/Thermo). Small aliquots of 2 mg/mL His10-UIM were fro-
zen in liquid nitrogen and stored at −80°C.
SYNAPTOSOME ISOLATION
Adult rat cortices rapidly frozen in liquid nitrogen and stored at 
−80°C were used for isolating synaptosomes, based on standard pro-
tocols (Gordon-Weeks, 1987) with buffer modiﬁ  cations to stabilize 
proteasomes. The procedure is schematically represented in Figure 1. 
Brieﬂ  y, cortices from four rats were homogenized in a motor-driven 
Potter-Elvehjem homogenizer in 30 mL buffer A (20 mM HEPES, 
0.32 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 mM DTT, protease 
and phosphatase inhibitors, pH 7.2). The homogenate was centri-
fuged at 1000 × g for 5 min, and the supernatant was collected as S1 
(if cloudy, centrifuged one more time). S1 was centrifuged at 
12,000 × g for 20 min, and the pellet (P12) was resuspended in buffer 
A and centrifuged again at 12,000 × g for 20 min. The synaptosome 
pellet (P12’) was resuspended in 11 mL buffer A with 1% NP-40 
using a Potter-Elvehjem homogenizer to disrupt the vesicles and 
extract proteins. This was followed by centrifugation at 18,000 × g Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  3
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for 10 min, and then at 100,000 × g for 1 h to sediment clathrin com-
plexes and debris. The supernatant (S100) was collected as synapto-
somal extract. To collect the cytosolic extract, supernatant S12 was 
centrifuged at 100,000 × g to remove microsomes. The supernatant 
was collected as cytosolic extract and supplemented with 1% NP-40. 
Synaptosomal protein yield from four cortices was ∼50 mg.
PROTEASOME PURIFICATION
The puriﬁ  cation of 26S proteasomes was conducted at 4°C. First, 
cytosolic or synaptosomal extracts (20 mg total protein) were incu-
bated for 2 h with 1 mg GST-UBL and 200 µL glutathione sepharose 
4B. After transferring to a gravity-glow column, resins were washed 
with 20 mL buffer A plus 0.5% NP-40, followed by 30 mL of buffer 
B plus 1 mM ATP and 5 mM MgCl2. Proteasomes were eluted by a 
20-min incubation with 250 µL His-UIM (2 mg/mL, with 2 mM 
ATP), and repeated one more time. The combined eluate was incu-
bated with 120 µ Ni-NTA for 20 min, and passed through 0.22-µm 
spin-ﬁ  lters (ultrafree MC, Millipore). The ﬁ  ltrate contained puri-
ﬁ  ed 26S proteasomes. For control samples, 0.7 mg GST was sub-
stituted for GST-UBL in the puriﬁ  cation procedure.
To deplete the cell extract of 26S proteasomes, GST-UBL was 
added to cell extracts (50 µg/1 mg of total protein) and incubated 
with glutathione sepharose. To sediment proteasomes, cell extracts 
were pre-cleared at 100,000 × g for 1 h, followed by centrifugation 
at 100,000 × g for 6 h. Pellets were redissolved in 50 mM Tris pH 
7.5, 6 M urea, and 1% SDS.
TISSUES AND NEURONAL CULTURES
Cortex, liver and kidney were dissected from 4- to 6-weeks old male 
Sprague-Dawley rats. Dissociated hippocampal neurons were pre-
pared and maintained as previously described (Aakalu et al., 2001). 
Brieﬂ  y, hippocampi from postnatal day 0 to 2 rats were dissected out 
and dissociated by papain and plated at a density of 70,000 cells/cm2 
onto poly-D-lysine-coated 60-mm culture dishes (Falcon). Cultures 
were maintained in Neurobasal A medium containing B-27 and 
Glutamax supplements (Invitrogen) at 37°C for 21–28 days before 
use. Tissue extracts were prepared in buffer A (20 mM HEPES, 
0.32 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 mM DTT, protease and 
phosphatase inhibitors, pH 7.2) with 0.2% NP-40, using motor-
driven Potter-Elvehjem homogenizers. Extracts of cultured neurons 
were prepared in buffer A with 0.5% NP-40, using glass dounce 
homogenizers. Extracts were cleared by centrifugation at 18,000 × g 
for 15 min to remove nuclei and cell debris, and protein concentra-
tions were measured by Coomassie Plus protein assay (Pierce).
NATIVE GEL ELECTROPHORESIS
To resolve proteasomes in cell extracts, 2–5% gradient native gels 
were prepared using the mini-protean 3 system and acrylamide/Bis 
(37.5:1) from Bio-Rad. The gel formulation was modiﬁ  ed from pub-
lished protocols for discontinuous native gels (Dohmen et al., 2005) 
based on Tris-borate-EDTA buffer (TBE, 90 mM Tris base, 80 mM 
boric acid, 0.1 mM EDTA, pH 8.3). Each 1.5 mm, 10-well gradient 
gel was made by mixing 3.3 mL of the upper gel solution (70 mM 
Tris pH 6.8, 2% acrylamide, 0.06% APS, 0.12% TEMED) and 6.3 mL 
of lower gel solution (1X TBE, 5% acrylamide, 3.5% sucrose, 1 mM 
DTT, 1 mM ATP, 5 mM MgCl2, 0.05% APS, 0.1% TEMED). Samples 
were mixed with 4X loading buffer (100 mM Tris pH 8.0, 20% glyc-
erol) just before loading. Electrophoresis was carried out at 6–10°C, 
in TBE running buffer (with 0.5 mM DTT, 0.5 mM ATP and 2 mM 
MgCl2). The applied voltage was gradually increased with time (30 V 
for 30 min, 35 V for 1 h, 50 V for 1 h, 65 V for 2–4 h). To resolve 
isolated 26S proteasomes, 1.5 mm, 10-well 3–8% Tri-acetate gels 
(Invitrogen) were used. Gel loading buffer and running buffer were 
the same as above. Electrophoresis was carried out at 4°C and 150 V 
for 4 h. For immunoblotting, proteins in native gels were transferred 
to PVDF membranes using Bio-Rad mini-protean 3 transfer system 
(buffer contains 25 mM Tris base, 192 mM glycine, 0.1% SDS) for 
4 h at 70 V (current limit: 350 mA) in a 4°C room.
IMMUNOBLOTTING AND SILVER STAINING
PVDF membranes with transferred proteins were blocked with 5% non-
fat milk in 50 mM Tris pH 7.5, 150 mM NaCl, and 0.05% Tween-20. 
Primary antibodies and HRP-conjugated secondary antibodies were 
applied in blocking reagent, followed by standard chemiluminescence 
detection. Band intensities on scanned ﬁ  lms were quantiﬁ  ed by den-
sitometry using the gel analysis function in ImageJ software. Silver 
staining was performed with SilverSNAP kit II (Pierce/Thermo).
PROTEASOME ACTIVITY ASSAY
26S proteasome activity in cell extracts was measured by a proteasome 
activity kit (Biomol/Enzo) and a ﬂ  uorometer, based on the hydrolysis of 
Suc-LLVY-AMC, a ﬂ  uorogenic substrate for chymotrypsin-like pepti-
dase activity. Native gels containing 26S proteasomes were incubated 
with reaction buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 1 mM ATP, 
FIGURE 1 | A schematic showing the preparation of synaptosomal and 
cytosolic extracts from rat cortices. We include an additional centrifugation 
step (1 h, 100,000 × g) after solubilization of synaptosomes with NP-40 and 
before incubation with the UBL -domain. Solubilization leads to binding of an 
unrelated clathrin complex to the UBL matrix, which complicates the mass 
spectrometric analysis (data not shown). The respective centrifugation step 
removes the bulk of this clathrin complex while the proteasome remains 
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1 mM DTT, 50 µM Suc-LLVY-AMC) for 30 min at 37°C. Fluorescent 
bands around 26S proteasomes were visualized and quantiﬁ  ed by stan-
dard gel-imaging systems for DNA staining by ethidium bromide.
MASS SPECTROMETRY
Puriﬁ  ed cytosolic and synaptic proteasome samples were digested 
with trypsin and the generated peptides were subjected to nanoscale-
microcapillary reversed phase liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using an in-house packed C18 125 µm I.D. 
capillary column and a hybrid linear ion trap/FT-ICR mass spec-
trometer (LTQ FT, Thermo Electron, Bremen, Germany) as described 
previously (Haas et al., 2006). Using the SEQUEST algorithm, MS/
MS data were searched against a concatenated target-decoy database 
created based on the rat IPI protein database including sequences 
of known contaminant proteins. We determined an overall protein 
false-discovery rate of 1% for the ∼100 proteins that made it above 
the unbiased ﬁ  lter thresholds (Elias and Gygi, 2007). The maximum 
number of incorrectly assigned proteins in the ﬁ  nal list of <50 pro-
tein is therefore 1. We believe that this false-discovery rate is hardly 
matched by other medium-to-large scale analysis methods currently 
available. Data in Tables 1 and 2 are compiled from two independent 
experiments using four rats each.
RESULTS
THE DISTRIBUTION OF PROTEASOME SPECIES IN THE CORTEX
Since very little is known about the proteasome content of the 
brain, we ﬁ  rst investigated what types of proteasomes may exist 
in the rat cortex. Using native gel electrophoresis followed by 
Table 1 | 26S proteasome subunits identiﬁ  ed by mass spectrometry.
IPI identiﬁ  er  Unigene identiﬁ  er  Gene name  Gene symbol  Cytosolic 26S  Synaptic 26S
        Unique   Sequence   Unique   Sequence 
       peptidesa  coverage   peptidesa  coverage 
         (%)    (%)
20S PARTICLE
IPI00191501.1  Rn.107278  Proteasome subunit alpha type 6 (α1)   Psma6  6  27  7  31
IPI00231757 .11  n/a  Proteasome subunit alpha type 2 (α2) Psma2  8  44  10  50
IPI00231046.8  Rn.11076  Proteasome subunit alpha type 4 (α3) Psma4  5  21  6  16
IPI00215243.3  Rn.105784  Isoform RC6-IL of proteasome   Psma7  11  46  12  44
    subunit alpha type 7 ( α4)        
IPI00191502.5  Rn.1276  Proteasome subunit alpha type 5 (α5) Psma5  7  30  7  30
IPI00191748.3  Rn.2668  Proteasome subunit alpha type 1 (α6) Psma1  13  55  13  52
IPI00476178.2  Rn.3997  Proteasome subunit alpha type 3 (α7) Psma3  6  28  6  25
IPI00188686.2  n/a  Proteasome subunit beta type 6 (β1) Psmb6  4  29 4  29
IPI00199980.1  Rn.3846  Proteasome subunit beta type 7 precursor (β2) Psmb7  4  16  4  16
IPI00214889.1  Rn.94551  Proteasome subunit beta type 3 (β3) Psmb3  5  33 5  33
IPI00188584.1  Rn.1981  Proteasome subunit beta type 2 (β4) Psmb2  10  56 6  41
IPI00230992.5  n/a  Proteasome subunit beta type 5 (β5)   Psmb5  12  49  12  51
IPI00191749.5  Rn.6016  Proteasome subunit beta type 1 precursor (β6) Psmb1  7  40  6  33
IPI00191505.3  Rn.6169  Proteasome subunit beta type 4 precursor (β7) Psmb4  8  43  8  43
19S PARTICLE
IPI00421600.7  Rn.1202  26S proteasome ATPase subunit 2 (Rpt1)  Psmc2  29  55  28  52
IPI00211733.1  Rn.10526  26S proteasome ATPase subunit 1 (Rpt2)  Psmc1  24  55  23  55
IPI00210158.1  Rn.11341  26S proteasome ATPase subunit 4 (Rpt3)  Psmc4  21  55  26  70
IPI00362105.2  Rn.103233  26S proteasome ATPase subunit 6 (Rpt4)  Psmc6  18  53  18  50
IPI00190392.3  Rn.11173  26S proteasome ATPase subunit 3 (Rpt5)  Psmc3  27  63  25  56
IPI00213587 .1  Rn.10972  26S proteasome ATPase subunit 5 (Rpt6)  Psmc5  24  52  24  55
IPI00370456.1  Rn.29909  26S proteasome non-ATPase subunit 2 (Rpn1)  Psmd2  40  46  39  46
IPI00212512.1  Rn.2891  26S proteasome non-ATPase subunit 1 (Rpn2)  Psmd1  31  37  29  41
IPI00370009.1  Rn.101332  26S proteasome non-ATPase subunit 3 (Rpn3)  Psmd3  31  48  33  54
IPI00198978.1  Rn.15873  26S proteasome non-ATPase subunit 12 (Rpn5)  Psmd12  27  50  28  50
IPI00370382.2  n/a  26S proteasome non-ATPase subunit 11 (Rpn6)  Psmd11  29  55  27  56
IPI00189463.1  Rn.103875  26S proteasome non-ATPase subunit 6 (Rpn7)  Psmd6  21  44  20  39
IPI00359611.2  Rn.20659  26S proteasome non-ATPase subunit 7 (Rpn8)  Psmd7  12  47  11  46
IPI00202283.1  Rn.16918  26S proteasome non-ATPase subunit 13 (Rpn9)  Psmd13  20  56  21  58
IPI00372125.3  Rn.161794  26S proteasome non-ATPase subunit 14 (Rpn11)  Psmd14  13  46  14  53
IPI00364072.1  Rn.137673  26S proteasome non-ATPase subunit 8 (Rpn12)  Psmd8  7  19  6  19
Note: auniqueness is deﬁ  ned solely by peptide sequence.Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  5
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Table 2 | Mass spectrometric identiﬁ  cation of proteins that co-purify with cytosolic and synaptic 26S proteasomes.
IPI identiﬁ  er  Unigene identiﬁ  er  Gene name  Gene symbol  Cytosolic 26S  Synaptic 26S
        Unique   Sequence   Unique   Sequence 
       peptidesa  coverage peptidesa  coverage 
         (%)      (%)
SUBSTOICHIOMETRIC PROTEASOME PROTEIN
IPI00367234.3  Rn.154631  Proteasome-associated protein ECM29  Ecm29  6  5  0  0
IPI00204510.5  Rn.9320  26S proteasome subunit Rpn13/ADRM1  Adrm1  3  6  3  6
IPI00200601.2 Rn.40430  Thioredoxin-like  protein  1/TRP32  Txnl1  13  56  14  60
19S ASSEMBLY FACTOR
IPI00194471.1  Rn.13415  26S proteasome non-ATPase subunit 5/S5b  Psmd5  14  38  13  37
IPI00231038.4  Rn.24127  26S proteasome non-ATPase   Psmd9  5  24  5  24
   subunit  9/Bridge-1/p27
E3
IPI00201213.3  Rn.12130  HECT, UBA and WWE domain-containing 1/ARF-BP1  Huwe1  51  21  54  21
IPI00365749.3  Rn.198497  Isoform 2 of ubiquitin-protein ligase E3A/E6-AP  Ube3a  20  27  16  24
IPI00768915.1  n/a  Potassium channel modulatory factor 1  Kcmf1  4  27  4  23
DUB
IPI00734588.1  Rn.40424  Ubiquitin carboxyl-terminal hydrolase L5/UCH37  Uchl5  7  26  5  23
IPI00207657 .1 Rn.44078  Ubiquitin  speciﬁ  c protease 5/isopeptidase T  Usp5  33  46  38  48
IPI00372303.3 Rn.72721  Ubiquitin  speciﬁ  c protease 7/HAUSP  Usp7  8  13  12  17
IPI00367362.3  n/a Ubiquitin  speciﬁ  c protease 13  Usp13  9  26  8  24
IPI00204532.2 Rn.11790  Ubiquitin  speciﬁ  c protease 14  Usp14  20  43  17  37
UPS
IPI00382052.2  Rn.3474  Isoform 2 of TAX1-binding protein 1/T6BP  Tax1bp1  0  0  3  6
IPI00194561.1  Rn.107103  Isoform 1 of sequestosome-1/p62  Sqstm1  6  28  5  17
N-END RULE
IPI00359416.3  Rn.37755  Retinoblastoma protein associated factor   Ubr4  66  18  74  19
   p600/RBAF600/UBR4
VCP COMPLEX
IPI00212014.2 Rn.98891  Valosin-containing  protein/p97  Vcp  18  28  30  41
IPI00204786.1  Rn.203087  Fas-associated factor 1  Faf1  11  23  11  21
CHAPERONE
IPI00207355.3  Rn.211303  Heat shock-related 70 kDa protein 2  Hspa2  4  9  4  9
VESICLE
IPI00204644.1  Rn.107689  Isoform B of synaptosomal-associated protein 25   Snap25  0  0  11  50
IPI00394488.2 Rn.203179  Glioblastoma  ampliﬁ  ed sequence/NIPSNAP2  Gbas  6  31  6  26
CYTOSKELETON
IPI00231407 .4 Rn.11247  Isoform  A  of  drebrin  Dbn1  0  0  1  4
IPI00197579.1  Rn.2458  Isoform 1 of tubulin beta 5  Tubb5  5  17  4  15
IPI00195673.1  Rn.98430  Tubulin beta 6  Tubb6  4  13  3  10
PHOSPHOPROTEIN BINDING
IPI00230835.4  Rn.29936  14-3-3 protein gamma  Ywhag  0  0  1  6
IPI00324893.4  Rn.1292  14-3-3 protein zeta/delta  Ywhaz  1  6  1  6
RASGEF
IPI00200118.4  Rn.53868  Isoform 2 of GRIP1-associated protein 1/GRASP-1  Gripap1  0  0  1  2
UNKNOWN
IPI00188755.4  Rn.106046  Caspase recruitment domain-containing protein  Fam188a  4  12  4  14
CLATHRIN COMPLEXb
IPI00193983.1 Rn.3589  Clathrin  heavy  chain  Cltc  0  0  12  11
IPI00203346.4  n/a  AP-2 complex subunit alpha-1  Ap2a1  0  0  1  2
IPI00471901.3  Rn.34928  AP-2 complex subunit alpha-2  Ap2a2  0  0  3  6
IPI00231502.3  Rn.56138  Isoform 2 of AP-2 complex subunit beta-1  Ap2b1  0  0  2  2
IPI00196530.1  Rn.3172  AP-2 complex subunit mu-1  Ap2m1  0  0  2  6
IPI00358691.2  Rn.162085  Epidermal growth factor receptor pathway   Eps15  0  0  3  6
    substrate 15 isoform B
MITOCHONDRIAc
IPI00196750.1 Rn.106922  Single-stranded  DNA-binding  protein,  mitochondrial    Ssbp1  0  0  4  40
auniqueness is deﬁ  ned solely by peptide sequence.
bThe clathrin complex appears to directly bind to GST-UBL independent of proteasome.
cMitochondrial proteins may be contaminants of synaptosomes. Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  6
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immunoblotting against 19S and 20S subunits, we found  doubly-
capped 26S, singly-capped 26S, and 20S proteasome in rat cortical 
extracts (Figure 2A). Their relative abundance in cortex, kidney, 
liver and Hela cells is quantiﬁ  ed and summarized in Figure 2B. 
Interestingly, the level of doubly-capped 26S proteasome was 
higher in the cortex than in other cell types (p < 0.01 by Tukey’s 
test). Additionally, we detected free 19S particles in these cell types, 
as well as a smaller complex containing the 19S subunit Rpt1 
(Figure 2A). We characterized this complex from liver extracts 
by tandem mass spectrometry (LC-MS/MS) and found S5b, Rpn1, 
Rpt1 and Rpt2. This complex has been recently shown to be an 
intermediate in 19S assembly (Funakoshi et al., 2009; Kaneko et al., 
2009; Le Tallec et al., 2009; Park et al., 2009; Roelofs et al., 2009; 
Saeki et al., 2009).
PROTEASOME INTEGRITY AFTER SUBCELLULAR FRACTIONATION
Next, we investigated if proteasomes in different subcellular com-
partments have different properties by comparing cytosolic and 
synaptic 26S proteasomes. Slight modiﬁ  cations of standard proto-
cols for isolating cytosolic and synaptosomal fractions (Figure 1) 
were sufﬁ  cient to preserve proteasome integrity, as assessed by native 
gel electrophoresis (Figure 3A) and enzymatic assays (Figure 3C). 
When cytosolic and synaptosomal extracts were incubated with 
GST-UBL and glutathione sepharose, the ﬂ  ow-through fraction was 
depleted of 19S-subunit Rpt1 protein (Figure 3B). Thus GST-UBL 
afﬁ  nity capture provides an efﬁ  cient method to purify the entire 
population of 26S proteasomes without apparent bias towards a 
speciﬁ  c subset. By contrast, there was a high amount of α7 subunit 
remaining in the ﬂ  ow-through (Figure 3B), which was consist-
ent with the abundance of free 20S particles (which lack afﬁ  n-
ity for ubiquitin or UBL-proteins), as detected in the native gel 
(Figure 3A). Also, when GST-alone was used, instead of GST-UBL, 
no proteasome or other complexes were detectable (Figure 4A).
Cytosolic and synaptic 26S proteasomes bound to the GST-UBL 
matrix were recovered by elution with His-UIM. When resolved 
by native gel electrophoresis and silver stained, each 26S sample 
showed only two bands, corresponding to doubly- and singly-
capped 26S proteasomes (Figure 4A), both of which remain enzy-
matically active (Figure 4C). Interestingly, the ratio of doubly- to 
singly-capped 26S was signiﬁ  cantly higher in the cytosol than in the 
synapse (Figure 4D). By sodium dodecyl sulfate-  polyacrylamide 
gel electrophoresis (SDS-PAGE) and silver staining, the band pat-
terns of the cytosolic and synaptic 26S proteasomes showed some 
differences, and very few proteins were found in GST controls 
(Figure 4B). Taken together, our data demonstrate that the dis-
tribution of proteasome species varies between different cells and 
tissues, as well as between different subcellular compartments of 
the brain.
FIGURE 2 | (A) Proteasome species found in different cell types. Extracts of 
HeLa cell (30 µg), rat cortex (60 µg), rat liver (40 µg) and rat kidney (50 µg) 
were resolved by 2–5% gradient native gel, immunoblotted against 19S 
subunit Rpt1, and reprobed against 20S subunit α7 . Protein bands were 
pseudo-colored and merged to illustrate the presence of proteasomes and 
related species (from top to bottom): doubly-capped 26S proteasome, singly-
capped 26S proteasome, free 19S particle and free 20S particle. 
A fast-migrating band corresponding to a subcomplex of the 19S containing 
Rpt1 protein was also observed. (B) The distribution of different proteasome 
species in (A), quantiﬁ  ed by densitometry (mean ± SEM, n = 6). The 
experiment was performed independently six times with tissues from three 
animals. By one-way ANOVA and Turkey’s multiple comparison test, doubly-
capped 26S levels in cortex are found to be signiﬁ  cantly higher (p < 0.01) than 
those in liver, kidney or HeLa cells.Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  7
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The GST-UBL capture method offers several advantages 
over proteasome-puriﬁ  cation strategies based on tandem afﬁ  n-
ity puriﬁ  cation (TAP) tags (Krogan et al., 2004; Guerrero et al., 
2006; Wang et al., 2007). TAP tag requires genetic manipulation 
and the tag may affect proteasome properties, while GST-UBL 
can efﬁ  ciently capture endogenous proteasomes from almost any 
biological source. Instead of tandem afﬁ  nity chromatography, a 
one-step elution using His-UIM yields functionally intact, highly-
puriﬁ  ed proteasomes which can be used for further enzymatic 
characterizations.
IDENTIFYING PROTEASOME-INTERACTING PROTEINS BY MASS 
SPECTROMETRY
Because the 26S proteasomes isolated from the cytosol and the 
synaptosome were highly puriﬁ  ed, it was possible to determine 
their compositions and the nature of the associated proteins by 
trypsin digestion and LC-MS/MS. These proteasome puriﬁ  cations 
were carried out in the absence of salt to maximize the content 
of   proteasome-associated proteins (Besche et al., 2009). Proteins 
bound to the GST-UBL sample that matched proteins bound by 
GST-alone were non-speciﬁ  c contaminants that interacted with 
the matrix and were not analyzed further. The remaining identiﬁ  ed 
proteins represented either stoichiometric proteasome subunits 
(Table 1) or 26S proteasome-interacting proteins (Table 2). There 
were no discernible differences in proteasome subunits between 
the cytosol and synaptosome, and no immunoproteasome subu-
nits were detected. Among the ∼30 interacting proteins identiﬁ  ed, 
one protein ECM29 was restricted to cytosolic proteasomes, and 
ﬁ  ve proteins (TAX1BP1, SNAP-25, drebrin, GRASP-1, 14-3-3γ) 
were found only in synaptic proteasomes. Those interactors shared 
between the two proteasome populations include several ubiquitin 
ligases (E3s), DUBs, molecular chaperones, and components of 
the UPS.
During puriﬁ  cation, the majority of ubiquitylated substrates 
associated with 26S proteasomes were removed because they 
became bound to His-UIM proteins on Ni-NTA resins as previously 
reported (Besche et al., 2009). Consequently, neither ubiquitin nor 
ubiquitin conjugates were detected in puriﬁ  ed 26S samples. Proteins 
listed in Table 2, therefore, most likely represent true proteasome-
interacting proteins, not transiently-associated proteasome sub-
strates. Some of these proteins have previously also been reported 
to interact with proteasomes from non-neuronal cells (Table 3); 
some appear to be brain-speciﬁ  c, such as the ubiquitin-binding 
factor TAX1BP1, the E3 enzyme KCMF1, and the synaptic vesicle 
protein SNAP-25.
VALIDATION OF PROTEASOME-INTERACTIONS
A few proteins (such as drebrin and GRASP-1) listed in Table 2 
were identiﬁ  ed only by a single matching peptide, and we wanted to 
validate that they were bona ﬁ  de interactors using an independent 
approach. We were able to conﬁ  rm their presence in puriﬁ  ed pro-
teasome preparations by Western blotting using speciﬁ  c antibod-
ies (Figure 5A). In addition, we utilized a co-sedimentation assay 
to independently assess (in the absence of GST-UBL) if proteins 
listed in Table 2 are indeed associated with proteasomes. When 
cytosolic and synaptic extracts were subjected to centrifugation at 
100,000 × g for 6 h, 20S and 26S proteasomes were largely found in 
the pellet fraction (Figure 5C). Under this condition, true proteas-
ome-interacting proteins should also sediment with the proteasome 
in the pellet, and a total of seven putative interacting proteins from 
Table 2 were tested. These included three ubiquitin ligases, HUWE1 
(HECT, UBA and WWE domain containing 1), UBE3A (E6-associ-
ated protein, E6-AP), and KCMF1 (potassium channel modulatory 
factor 1); USP14 (ubiquitin-speciﬁ  c protease 14, a DUB); PSMD9, 
a recently identiﬁ  ed 19S assembly factor (Funakoshi et al., 2009; 
Kaneko et al., 2009; Saeki et al., 2009); ECM29, the only proteasome 
protein detected exclusively in the cytosol; and 14-3-3γ, which binds 
phosphoproteins and was found only in synaptic proteasomes. All 
seven proteins co-  sedimented with proteasomes as expected, and 
their subcellular distribution agrees very well with the mass spec-
trometry results (Figure 5C). This validates our puriﬁ  cation and 
identiﬁ  cation strategy.
In our preliminary experiments, it was observed that the clath-
rin complex can bind to GST-UBL independently of the protea-
some in puriﬁ  cations from synaptosomes and microsomes (data 
FIGURE 3 | (A) Proteasome integrity after subcellular fractionation. Cytosolic 
(Cyt) and synaptic (Syn) extracts prepared from rat cortices were resolved by 
2–5% gradient native gel, immunoblotted against 19S subunit Rpt1, and 
reprobed for 20S subunit α7 . Singly-, doubly-capped 26S, 20S proteasomes 
and free 19S were detected in both fractions. (B) Efﬁ  cacy of 26S 
proteasome isolation by UBL afﬁ  nity chromatography. Cytosolic (Cyt) and 
synaptic (Syn) extracts were incubated with GST-UBL and glutathione 
sepharose. The input (IN) and ﬂ  ow-through (FT) materials were analyzed by 
SDS-PAGE and immunoblotted against Rpt1 and α7 . The depletion of Rpt1 
from the ﬂ  ow-through indicated that most 26S proteasomes and 19S 
particles remained intact during subcellular fractionation and were captured 
with high efﬁ  ciency. The high remaining level of α7 subunit in the ﬂ  ow-
through is consistent with the abundance of free 20S particles detected in 
(A). (C) Cytosolic and synaptosomal extracts contain active 26S 
proteasomes. Cytosolic (Cyt) and synaptic (Syn) extracts isolated from rat 
cortices were resolved by 2–5% gradient native gel, followed by incubation 
with Suc-LLVY-AMC, a ﬂ  uorogenic proteasome substrate. Active 26S 
proteasomes appear as ﬂ  uorescent bands, corresponding to doubly- and 
singly-capped 26S proteasomes.Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  8
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not shown). In this study, ultracentrifugation for 1 h at 100,000 × g 
before the UBL-puriﬁ  cation efﬁ  ciently removed most of the clath-
rin complex from solubilized synaptosomal proteasomes; however, 
traces were still detectable by LC-MS/MS. Thus, we do not con-
sider clathrin and related vesicular proteins as 26S proteasome 
 interactors  (Table 2), although our data cannot formally rule 
out the possibility of such interactions. The VCP/p97 complex, 
which is also a key component of the UPS, has been previously 
observed to bind proteasomes in both muscle and yeast (Verma 
et al., 2000; Besche et al., 2009). However, it also directly binds to 
the UBL-domain in complex with associated cofactors in muscle 
extracts (Besche et al. 2009). We failed to detect by Western blot-
ting any appreciable interaction between VCP and the prepara-
tion of GST-UBL used in this study (Figure 5B). The relatively 
low levels of VCP and one of its associated factors detected by 
mass spectrometry in puriﬁ  ed 26S proteasomes are thus likely a 
result of VCP-proteasome interaction in brain, although we can-
not formally rule out the potential interaction between VCP and 
the GST-UBL matrix.
It is also noteworthy that we could not detect by mass spec-
trometry parkin (an E3 mutated in autosomal-recessive juvenile 
Parkinsonism) and PI31 (which may function as an inhibitor of the 
20S proteasome), which have been reported to interact with pro-
teasomes in non-neuronal cells (McCutchen-Maloney et al., 2000; 
Sakata et al., 2003). Also, neither of these proteins co-sedimented 
with proteasomes (Figure 5C). These ﬁ  ndings further illustrate the 
speciﬁ  city of our puriﬁ  cation strategy and the differences between 
proteasome interactors in different cell types.
FIGURE 4 | (A) Purity of isolated 26S proteasomes. Cytosolic (Cyt) and synaptic 
(Syn) 26S proteasomes were isolated using GST-UBL/His-UIM. In control (Con) 
experiments, GST was added instead of GST-UBL. Samples were resolved by 3–
8% gradient native gel and silver-stained. (B) The same samples in (A) analyzed 
by SDS-PAGE, followed by silver staining. The control experiments showed only 
a few non-speciﬁ  c protein bands. (C) Activity of isolated proteasomes. 
Chymotrypsin-like peptidase activity of isolated 26S proteasomes resolved by 
3–8% native gel was assayed with Suc-LLVY-AMC. (D) Differences in capped 
proteasome ratios. Silver-stained 26S proteasome bands in (C) were quantiﬁ  ed 
by densitometry. The ratio of doubly- over singly-capped 26S was signiﬁ  cantly 
higher in the cytosol (Cyt) than the synaptosome (Syn) (mean ± SEM, n = 4, 
*p < 0.05 by paired t-test).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  9
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NMDA TREATMENT SUPPRESSES NEURONAL UPS ACTIVITY
Several forms of synaptic plasticity have been shown to require 
activity of the UPS (Fonseca et  al., 2006; Hou et  al., 2006; 
Karpova et al., 2006), and hence there is a growing interest in 
understanding how neuronal activity regulates different aspects 
of the UPS (Ehlers, 2003; Patrick et al., 2003; DiAntonio and 
Hicke, 2004; Bingol and Schuman, 2006; Bingol et al., 2010). 
However, the regulation of proteasomes by synaptic activity 
is hindered by a lack of basic knowledge about neuronal pro-
teasomes. The biochemical characterization of brain proteas-
omes described above now provides a basis for investigating 
the interplay between proteasomes and synaptic plasticity. To 
induce long-term synaptic plasticity, we exposed cultured hip-
pocampal neurons to 20 µM NMDA for 3 min. NMDA has been 
shown to induce rapid internalization of glutamate receptors (Li 
et al., 2004; Delgado et al., 2007), resulting in depressed neuro-
transmission that lasts for hours, which is also called “chemical 
long-term depression” (chemical LTD) (Lee et al., 1998). This 
is a well-established protocol to investigate synaptic plasticity 
in cultured hippocampal neurons and hippocampal slices (Lee 
et al., 1998; Li et al., 2004; Lu and Ziff, 2005; Delgado et al., 2007; 
Davidson et al., 2009).
Following the exposure of neurons to NMDA, we observed a 
long-lasting reduction in 26S proteasome activity assayed with 
fluorogenic peptide substrates (Figures 6A,B). The decrease was 
statistically significant compared to untreated neurons at 4 h 
post-NMDA treatment. A decrease in 26S proteasome activity 
should lead to the accumulation of ubiquitin-protein conju-
gates, as occurs upon treatment with proteasome inhibitors, 
provided there were no global changes in the rates of ubiq-
uitylation as well as deubiquitylation. Therefore, we measured 
the levels of ubiquitin-protein conjugates in neurons following 
NMDA treatment. Surprisingly, the content of ubiquitin-protein 
conjugates was significantly reduced 4 h after NMDA exposure, 
while levels of free (monomeric) ubiquitin remained unaffected 
(Figures 6C,D).
Table 3 | Comparison of proteasome composition from different mammalian cells determined by proteomic approaches.
Gene symbola This  study Muscleb HEK293c HEK293d Synaptosome  (no  ATP)e
 Cytosol  Synaptosome       
ADRM1 X X  X  X  X 
DBN1   X      
ECM29 X    X    
FAF1 X  X      X 
FAM188A X  X       
GBAS X  X  X    
GRIP1AP1   X       
HSPA2 X  X    X  
HUWE1 X X  X    X 
KCMF1 X  X        X
PSMD5 X X       
PSMD9 X X       
SNAP25   X        X
SQSTM1 X  X  X    X 
TAX1BP1   X       
TXNL1 X  X      X 
TUBB5 X  X       
TUBB6 X  X       
UBE3A X  X  X X X 
UBR4 X  X  X   X 
UCHL5 X  X  X X X 
USP13 X  X      X 
USP14 X  X  X X X X
USP5 X  X  X   X  X
USP7 X  X  X    
VCP X  X  X     
YWHAG   X       
YWHAZ X X    X   
aGene symbols approved by HUGO (Human Genome Organization) gene nomenclature committee.
bBesche et al. (2009).
cWang et al. (2007), Wang and Huang (2008).
dScanlon et al. (2009).
eBingol et al. (2010).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  10
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The similar decrease in 26S proteasome activity and ubiquitin-
conjugate levels 4 h after NMDA treatment strongly implies that 
protein ubiquitylation also decreased and suggests a coordinated 
reduction in the rate of proteolysis mediated by the ubiquitin-pro-
teasome pathway during NMDA-induced plasticity. These results 
are consistent with earlier reports showing that activity-blockade 
with TTX leads to decreased proteasome activity (Djakovic et al., 
2009) and lower ubiquitin-conjugate levels (Ehlers, 2003).
NMDA TREATMENT CAUSES 26S DISASSEMBLY AND E3 DISSOCIATION
We next investigated the mechanisms responsible for the long-
lasting reduction in UPS activity. In yeast, during stationary 
phase when proteolysis by the UPS appears to be down-regu-
lated, 26S proteasomes gradually disassemble into 19S and 20S 
particles (Bajorek et al., 2003). Hence, we assessed if similar 
changes occur in neurons by native gel analysis. As expected, 
there was a shift from 26S proteasomes to 20S proteasomes 4 h 
after NMDA exposure, indicating the disassembly of 26S pro-
teasomes (Figures 7A,C).
The above findings suggest that the reduction in 26S levels 
after NMDA exposure in neurons is coordinated with reduced 
protein ubiquitylation (Figures 6C,D). One possible mechanism 
is that some of the cell’s many ubiquitin ligases may be down-
regulated following NMDA treatment. We therefore focused 
on the three proteasome-bound E3s identified earlier in this 
study. The degree of association between the E3s and the pro-
teasome was determined by their co-sedimentation properties 
(at 100,000 × g for 6 h). Two of these E3s, UBE3A and HUWE1, 
were found to be largely dissociated from proteasomes at 4 h 
after NMDA exposure, while the ligase KCMF1 was not signifi-
cantly affected (Figure 7D). The loss of specific ligases from the 
proteasome may potentially decrease proteasome activity and 
FIGURE 5 | (A) Veriﬁ cation of drebrin and GRASP-1 as interactors of synaptic 
proteasomes. Both proteins were initially detected in synaptic proteasomes by 
mass spectrometry, based on a single matching peptide (Table 2). These 
speciﬁ  c interactions are conﬁ  rmed by SDS-PAGE and Western blotting. 
Synaptosome (Syn)-derived proteasomes (26S) and control (Con) puriﬁ  cations 
using only GST are probed with speciﬁ  c antibodies against drebrin, GRASP-1, 
and 19S subunit Rpt1. (B) The VCP complex does not interact appreciably with 
GST-UBL. 26S proteasomes from the cytosolic (Cyt) and synaptic (Syn) extracts 
were puriﬁ  ed by the GST-UBL/His-UIM method. The input (IN) material and 
puriﬁ  ed 26S proteasomes were immunoblotted against VCP and Rpt1. The 
amount of VCP captured by the GST-UBL matrix was undetectable by Western 
blot in three independent experiments. (C) Veriﬁ  cation of proteasome-interacting 
proteins by co-sedimentation. Cytosolic (Cyt) and synaptosomal (Syn) extracts 
were subjected to centrifugation at 100,000 × g for 6 h. The supernatant (Sup) 
and pellet (Pel) materials were loaded at 1:1 ratio and resolved by SDS-PAGE. 
The sedimentation of proteasomes was conﬁ  rmed by the high levels of 20S 
subunit α7 and 19S subunit Rpt1 in the pellet fraction. Proteins identiﬁ  ed by 
mass spectrometry in 26S proteasomes (26S MS) from the cytosol and the 
synaptosome are indicated by the positive sign. Agreement between mass 
spectrometry data and co-sedimentation data was observed for all seven 26S-
interacting proteins (UBE3A, HUWE1, KCMF1, USP14, PSMD9, ECM29, 14-3-
3γ) probed by speciﬁ  c antibodies (see Materials and Methods). Parkin and PI31 
did not show appreciable association with brain proteasomes. Results shown 
here are representative of three experiments.Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  11
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alter substrate specificity (Kraut et al., 2007). It is noteworthy 
that UBE3A (E6-AP) was the first E3 to be implicated in synaptic 
plasticity (Jiang et al., 1998), and it can target synaptic protein 
Arc for degradation to control glutamate receptor endocytosis 
(Greer et al., 2010). Our data implies that UBE3A may provide 
a mechanistic link between NMDA receptor signaling and pro-
teasome activity.
DEGRADATION OF 19S PARTICLES AND PROTEASOME-BOUND E3s
What is the fate of the 19S particles dissociated from 26S proteas-
omes? In yeast, during stationary phase, free 19S particles appear 
to remain intact and available for reuse when growth is reinitiated 
(Bajorek et al., 2003). However, in neurons during NMDA-induced 
plasticity, we detected a simultaneous decrease in free 19S parti-
cles (Figure 7C), suggesting the further disassembly or degrada-
tion of the 19S. Therefore, we investigated if the subunits of the 
disassembled 19S existed as free proteins in the cytosol or were 
rapidly degraded. Total 19S subunit levels in the lysate were found 
to decrease signiﬁ  cantly (Figures 8A,B), and no free subunits were 
detectable (Figure 7B). Altogether, these data suggest that 19S par-
ticles released from 26S proteasomes were degraded within 4 h of 
NMDA treatment.
In addition, we investigated the fate of the E3s that dissociated 
from the proteasome. Like the 19S particle, UBE3A and HUWE1 
were degraded by 4 h after NMDA exposure, as indicated by lower 
protein levels than untreated controls (Figures 8C,D). On the other 
hand, the E3 KCMF1 did not show either signiﬁ  cant degradation 
or dissociation from the proteasome (Figures 7D and 8D).
In contrast to acute NMDA treatment, which is often associated 
with a depression of synaptic transmission, other pharmacologi-
cal manipulations that suppress neuronal activities do not elicit 
the degradation of 19S particles (Figure 9). These manipulations 
included adding DHPG to induce metabotropic glutamate receptor 
(mGluR)-dependent LTD, applying TTX to block action poten-
tials, and TTX + APV + CNQX to block both action potentials and 
miniature synaptic events These results suggest that only NMDA 
receptor signaling may be speciﬁ  cally required for the degradation 
of 19S particles, in addition to reduced synaptic activity.
19S PARTICLES ARE DEGRADED BY A PROTEASOME-DEPENDENT 
MECHANISM
Although the proteasome is the major site for protein degrada-
tion in the cell and comprises about 2% of cell proteins, surpris-
ingly little is known about the catabolism of the proteasome 
FIGURE 6 | UPS activity is reduced after NMDA treatment. (A) Cultured 
hippocampal neurons were treated with 20 µM NMDA for 3 min, a standard 
procedure for inducing chemical LTD. Whole-cell lysates were prepared at 
30 min or 4 h post-treatment. (B) Decreases in proteasome activity after NMDA 
exposure. 26S proteasome activities in neuronal lysates were assayed with Suc-
LLVY-AMC (see Materials and Methods). NMDA-treated samples (30’ and 4 h) 
are normalized to the untreated control (Con) (mean ± SEM, n = 5, *p < 0.05 by 
paired t-test). (C) Ubiquitin conjugates decrease after NMDA exposure. Neuronal 
lysates resolved by SDS-PAGE were blotted using antibodies against ubiquitin-
protein conjugates (Ub conj) and free monomeric ubiquitin (free Ub). Tubulin 
served as the loading control. (D) Signals in (C) quantiﬁ  ed by densitometry 
(n = 5, *p < 0.05 by paired t-test).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  12
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itself. A prior study suggested that 20S proteasomes undergo 
a slow turnover in the liver via lysosomal digestion (Cuervo 
et al., 1995). To our knowledge, no study has examined the 
catabolic fate of 19S particles. Thus, we tested if in response 
to NMDA treatment they are degraded by the proteasome or 
the lysosomal system.
We tested many different combinations of proteasome 
and   lysosome inhibitors and examined their effects on the 
  degradation  of 19S   particles induced by NMDA (Figure 10). 
Proteasome  inhibitors including MG132 and epoxomicin + lacta-
cytsin were the most   effective in preventing the NMDA-induced 
degradation of the 19S. On the other hand, the lysosome inhibi-
tors   chloroquine and   concanamycin A, which   prevent lysosomal 
acidiﬁ  cation, showed no effects on 19S degradation.
In summary, our data indicate that the reduction in UPS activ-
ity after NMDA exposure occurs through several mechanisms, 
including a reduction of 26S proteasome levels and activities, 
dissociation of 19S particles from the 26S and their subsequent 
degradation, decrease of protein–ubiquitin conjugates, and deg-
radation of the E3 enzymes released from the proteasome. The 
degradation of 19S particles occurs via proteasomal and not lyso-
somal mechanisms.
DISCUSSION
CYTOSOLIC AND SYNAPTIC PROTEASOMES HAVE DIFFERENT 
COMPOSITIONS
In this study, we isolated and characterized cytosolic and synaptic 
26S proteasomes from the rat cortex. One unexpected observation 
was that the ratio of doubly- to singly-capped 26S proteasomes was 
higher in the cytosol than in the synapse. Both forms can degrade 
ubiquitylated proteins (Kriegenburg et al., 2008), but the functional 
differences between doubly- and singly-capped 26S have not been 
established. For example, it is unknown whether they differ in rates 
of degradation or in their substrate afﬁ  nity or speciﬁ  city. Singly-
capped 26S has an exposed 20S α-ring that allows it to interact 
with additional regulators such as PA28 or PA200 (Rechsteiner 
and Hill, 2005). These interacting complexes are likely to dissociate 
during native gel electrophoresis. Consequently, the singly-capped 
species observed in our study may in fact represent hybrid 26S 
(e.g. 19S-20S-PA28) in vivo. Unfortunately, the functional roles 
of these factors on the proteasome are also not well understood. 
They may facilitate degradation of speciﬁ  c substrates, e.g. PA28γ 
has been reported to promote the ubiquitin-independent degra-
dation of the transcriptional coactivator SRC-3 (Li et al., 2006). 
Thus, it is possible that some singly-capped 26S proteasomes in 
FIGURE 7 | Changes in proteasome complexes after NMDA exposure. (A) 
The disassembly of 26S proteasomes. Neuronal lysates collected at 30’ and 4 h 
post-NMDA (20 µM, 3 min) were resolved by 2–5% gradient native gel and 
immunoblotted against 20S subunit α7 and 19S subunit Rpt1. (B) Changes in 
proteasome-associated proteins. Lysates from (A) were subjected to 
ultracentrifugation to sediment proteasomes. Equal amounts of supernatant 
(Sup) and pellet (Pel) materials were analyzed by SDS-PAGE. The sedimentation 
property of proteasome-interacting proteins (HUWE1, UBE3A, KCMF1, PA28α) 
was examined by Western blotting. Parkin and PI31 were not detected in the 
pellet. (C) Quantiﬁ  cation of changes in proteasome distributions in (A) by 
densitometry (n = 6, mean ± SEM, *p < 0.05 by paired t-test). (D) The graph 
represents the sedimentation data in (B). The protein level in the pellet is divided 
by the total level (supernatant + pellet), and the results are plotted (n = 4, 
*p < 0.05 by paired t-test).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  13
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 association with such cofactors represent more specialized particles 
that serve distinct functions in different subcellular locations, such 
as the synapse.
The 28 26S-associated proteins we found in rat cortex differ 
considerably from those identiﬁ  ed by the same approach in rat 
muscle (Besche et al., 2009). Surprisingly, only 12 are identical, 
even though myocytes are also postmitotic. Protein degradation 
however, serves certain very different roles in neurons and skeletal 
muscle, which represents the major amino acid reservoir in mam-
mals. Unlike proteins in neurons, muscle proteins are mobilized 
through accelerated proteolysis in fasting or other stressful condi-
tions (Mitch and Goldberg, 1996). Also, the protein composition in 
skeletal muscles and neurons are very different, which may neces-
sitate the involvement of different factors to assist proteasome-
mediated degradation. Whether further differences in the spectrum 
of proteasome-associated proteins exist between different brain 
regions remains to be explored.
A surprising ﬁ  nding is that ECM29, which has been reported 
to stabilize the association of 19S and 20S particles (Leggett et al., 
2002; Kleijnen et al., 2007), is only present in the cytosolic 26S but 
not the synaptic 26S. No factor is known that promotes formation 
of doubly-capped 26S, but our data suggest ECM29 as a possible 
candidate.
By mass spectrometry, we identiﬁ   ed several proteasome-
 interacting proteins unique to synaptic 26S proteasomes (14-3-3γ, 
TAX1BP1, drebrin, SNAP-25), which may modulate proteoly-
sis in a synapse-speciﬁ  c manner. 14-3-3γ, which binds many 
  phosphoproteins in the cytosol (Bridges and Moorhead, 2004), 
may coordinate proteasome function with the protein phospho-
rylation events that regulate synaptic transmission (Malenka and 
Bear, 2004). TAX1BP1 is a ubiquitin-binding protein (Iha et al., 
2008; Shembade et al., 2008) that may promote substrate-protea-
some association at the synapse. It will be interesting to examine 
which synaptic proteins interact with TAX1BP1. Previous studies 
suggested that proteasomes are sequestered in dendritic spines 
by interacting with the actin cytoskeleton (Bingol and Schuman, 
2006). Our data suggests that the interaction may be partially 
mediated by drebrin, an important actin-binding protein in the 
spine (Takahashi et al., 2009). Moreover, proteasome-mediated 
proteolysis has been shown to regulate synaptic vesicle release 
in several ways (Willeumier et al., 2006; Yao et al., 2007). The 
interaction between synaptic proteasomes and SNAP-25, a key 
synaptic vesicle protein (DeBello et al., 1995; Montecucco et al., 
2005), may provide a mechanism for the proteolytic control of 
vesicle dynamics.
The various features of the proteasomes in the brain raise many 
obvious fundamental questions that unfortunately cannot now be 
answered due to the limits of our knowledge about the UPS. For 
example, as noted above, the functional differences (if any) between 
singly-capped and doubly-capped 26S is presently unknown, nor 
is it clear whether free 20S proteasomes play any signiﬁ  cant role in 
overall intracellular proteolysis by themselves (i.e. when not part of 
the 26S complex) or in the breakdown of speciﬁ  c proteins although 
an important role in eliminating  inherently structureless proteins has 
FIGURE 8 | Degradation of proteasome components after NMDA exposure. 
(A) The degradation of 19S subunits. Neuronal lysates collected at 30’ and 4 h 
post-NMDA were resolved by SDS-PAGE and probed for total levels of 20S 
subunit α7 , 19S subunit Rpt1, and VCP (an abundant UPS protein). Tubulin served 
as the loading control. (B) Quantiﬁ  cation of the results in (A) by densitometry 
(n = 6, mean ± SEM, *p < 0.05 by paired t-test). (C) Degradation of proteasome-
interacting E3s. Neuronal lysates from (A) were immunoblotted against E3s 
(HUWE1, UBE3A, KCMF1) and DUBs (USP14) that interact with proteasomes. 
(D) The graph represents protein levels in (C) normalized to α7 levels (n = 5, 
*p < 0.05 by paired t-test).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  14
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been proposed (Tsvetkov et al., 2009). Another fundamental issue 
raised by the present study is the role of the proteasome-associated 
ubiquitin ligases. Neurons, like other cells, contain many, perhaps 
hundreds of E3s, and the functional signiﬁ  cance of the localization of 
UBE3A, HUWE1 and KCMF1 on the proteasome is a major mystery. 
Presumably, the presence of a ubiquitylation system on the protea-
some allows more efﬁ  cient destruction of a substrate than if the sub-
strate is free in the cytosol (or nucleus or synapse) and has to diffuse 
or be delivered to the 26S for degradation. Interestingly, UBE3A has 
recently been implicated in degrading proteins important in synaptic 
plasticity (Greer et al., 2010). Alternatively, the presence of these E3s 
on the 26S may indicate a direct role in proteasome function, e.g. 
in remodeling proteasome-bound ubiquitin chains or enhancing 
processivity, as has been suggested for the E3, Hul5, which is associ-
ated with yeast 26S particle (Crosas et al., 2006). Finally, interpreta-
tion of the signiﬁ  cance of this spectrum of proteasome-interacting 
proteins, and differences between synaptic and cytosolic proteasomes, 
will be facilitated when we learn more about the proteins associated 
with the 26S in other mammalian tissues. Similar systematic analyses 
of these proteasomes have not yet been carried out.
NEURONAL ACTIVITY INFLUENCES PROTEASOME DEGRADATION AND 
INTERACTING E3s
Recent studies have shown that neuronal activity inﬂ  uences the 
activity of UPS in dendrites and synapses (Bingol and Schuman, 
2006; Djakovic et al., 2009). Our ﬁ  ndings further demonstrate that 
the global UPS activity of neurons can also be affected by neuronal 
activity. Neurons exposed to NMDA showed decreases in the lev-
els of ubiquitin conjugates in whole-cell lysates, which may result 
from decreased ubiquitylation or increased conjugate degradation. 
However, after NMDA treatment, the levels of 26S proteasomes 
decreased due to the degradation of 19S particles. One possible 
interpretation is that neurons reduce 26S proteasome levels when 
there are fewer substrates to degrade. We found that 19S degrada-
tion is catalyzed by proteasomes and not lysosomes. Although the 
detailed mechanism is not clear yet, it is likely that the 19S particle 
dissociates into individual subunits, which are then degraded by 
the proteasome. Presumably, this NMDA-induced destruction of 
proteasomes is a mechanism for suppressing overall proteolysis. 
The proteasome is generally assumed to be a long-lived cell con-
stituent, although the few prior studies (Cuervo et al., 1995) have 
only investigated turnover of 20S particles. In the NMDA-treated 
neurons, about a third of the 26S particles and up to 50% of the free 
19S were lost in four hours without any concomitant loss of the 20S 
particle. To our knowledge, this is the ﬁ  rst study to observe selective 
degradation of the 19S particle and the detailed mechanisms will 
be important to understand in future studies.
The selective degradation of the 19S also resulted in the appar-
ent shift from 26S to 20S proteasomes, which cannot degrade 
ubiquitylated proteins. The role(s) of free 20S in the cell is not 
clear since the entry of substrates into its proteolytic chamber 
is restricted by a gate formed by the N-terminal residues of the 
α-subunits (Smith et al., 2007; Tanaka, 2009). In vitro this gate 
is continually opening spontaneously and peptides or unfolded 
proteins can enter the 20S, though at a much lower rate than in 
the assembled 26S. Degradation of unfolded or inherently struc-
tureless proteins by the 20S has often been proposed to occur 
in vivo (e.g. after oxidative damage, or with aging) (Poppek and 
Grune, 2006; Tsvetkov et al., 2009), but clear evidence for such a 
role in vivo is lacking. On the contrary, there is strong evidence 
that most unfolded or oxidant-damaged proteins are degraded 
by a ubiquitin-dependent mechanism requiring the 26S protea-
some and VCP/p97 complexes (Medicherla and Goldberg, 2008). 
Whether having additional 20S proteasomes actually enhances 
proteolytic functions in neurons is another important issue for 
further study raised by these data.
FIGURE 9 | The degradation of 19S particles is speciﬁ  c to NMDA 
treatment. (A) Cultured hippocampal neurons were brieﬂ  y treated with 
NMDA (20 µM, 3 min) or DHPG (100 µM, 10 min), or persistently treated with 
TTX (2 µM) or TTX + CNQX + APV (2, 40, and 50 µM, respectively). Only the 
vehicle was added in control experiments (Con). Neuronal lysates were 
collected at 4 h after drug addition, and analyzed by SDS-PAGE and Western 
blot for the levels of 19S subunit Rpt1 and 20S subunit α7 . GAPDH served as 
loading control. (B,C) represent the results in (A) quantiﬁ  ed by densitometry. 
Rpt1 and α7 levels (mean ± SEM) were normalized to the control. Statistical 
signiﬁ  cance (*p < 0.05) was determined by paired t-test against the control 
(n = 8 for NMDA and DHPG, n = 4 for TTX and TTX + APV + CNQX). Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  15
Tai et al.  Characterization of brain proteasomes
PROTEASOMES AND SYNAPTIC FUNCTION
Several studies have shown that modifying synaptic strength requires 
the proteasomal degradation of synaptic proteins (Colledge et al., 
2003; Ehlers, 2003; Bingol and Schuman, 2004; Guo and Wang, 
2007). In particular, proteasome-mediated proteolysis is required 
for the endocytosis of glutamate receptors (Colledge et al., 2003; 
Patrick et al., 2003), after neurons are exposed to high concentra-
tions of glutamate or NMDA (Ehlers, 2000; Lee et al., 2004). Hence, 
the proteins interacting with synaptic proteasomes identiﬁ  ed in this 
study are likely to be important for synaptic regulation.
We found three E3s (KCMF1, HUWE1, and UBE3A) and ﬁ  ve 
DUBs (USP5, USP7, USP13, USP14, and UCH37) in association 
with synaptic proteasomes, which may help proteasomes function 
more efﬁ  ciently, help determine speciﬁ  city for certain types of con-
jugates, or insure the rapid elimination of ubiquitin chains released 
from the substrate (since free ubiquitin chains can inhibit proteaso-
mal degradation in vitro) (Finley, 2009). The proteasome-associated 
DUBs presumably function together with the Rpn11 subunit (a 
different type of DUB) to catalyze the disassembly of the ubiquitin 
chain and the recycling of free ubiquitin (Koulich et al., 2008). In 
particular, removal of Ubp6 (USP14 homolog) from yeast proteas-
omes leads to a failure to efﬁ  ciently remove the ubiquitin chain from 
substrates and the degradation of some of the attached ubiquitins 
(Hanna and Finley, 2007). USP14/Ubp6 also has an important regu-
latory role in controlling proteasome function (Finley, 2009), for 
example, together with the ATPases, it regulates gate opening and 
substrate entry in the 20S (Peth et al., 2009). In fact, there are mice 
with spontaneous mutations in USP14, called ataxia (axJ) mice, 
which develop synaptic dysfunction (Wilson et al., 2002; Anderson 
et al., 2005). Our identiﬁ  cation of USP14 on synaptic proteasomes 
supports the model that reduced synaptic levels of monomeric 
ubiquitin and ubiquitin conjugates observed in axJ mice (Chen 
et al., 2009) may be due to altered proteasomes that degrade the 
substrate-linked ubiquitin and fail to recycle it.
Since hundreds of E3s encoded in the mammalian genome 
appear to function without apparent association with the protea-
some (Semple, 2003), it will be important to learn what is special 
about the three E3s we identiﬁ  ed on synaptic proteasomes. Curiously, 
two of them have been previously linked to genetic disorders associ-
ated with mental retardation in humans. UBE3A mutations cause 
Angelman syndrome (Lalande and Calciano, 2007), and knockout 
mice lacking this E3 show defects in synapse morphology, glutamate 
receptor endocytosis, and LTP (Jiang et al., 1998; Dindot et al., 2008; 
Greer et al., 2010). HUWE1 mutations are found in X-linked mental 
retardation (Froyen et al., 2008). Since many mental retardation 
genes appear to be involved in synaptic dysfunction (Humeau et al., 
FIGURE 10 | The degradation of 19S particles is proteaosme-dependent. 
(A) Proteasome inhibitor MG132 (40 µM) was added to cultured hippocampal 
neurons 30 min before NMDA stimulation (20 µM, 3 min). After NMDA 
washed-out, MG132 was applied again for 4 h before neuronal lysates were 
collected. In control (Con) experiments, neurons were only treated with NMDA. 
Rpt1 levels were determined by SDS-PAGE and immunoblotting. GAPDH 
served as loading control. (B) 19S degradation induced by NMDA in (A) was 
quantiﬁ  ed by densitometry (n = 5, mean ± SEM). Statistical signiﬁ  cance 
(*p < 0.05) was determined by t-test assuming unequal variance. (C) The same 
experiments as in (A) and (B), performed with different combinations of 
proteasome inhibitors (2 µM epoxomicin; 10 µM lactacystin; 40 µM MG132) 
and lysosome inhibitors (150 µM chloroquine; 100 nM concanamycin A). 
Statistical signiﬁ  cance was determined using t-test (p-value is listed, or ns for 
not signiﬁ  cant, p > 0.05).Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  16
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2009), our data imply that UBE3A and HUWE1 mutations may 
cause synaptic defects by altering synaptic proteasome function. 
Interestingly, UBE3A and HUWE1 dissociate from 26S proteasomes 
and become degraded after neurons are exposed to NMDA. This 
simultaneous degradation of 19S particles and these bound E3s rep-
resents a novel mechanism of UPS regulation in mammalian cells. 
It will be important to determine what synaptic protein substrates 
are normally targeted for degradation by these two E3s, and which 
are presumably stabilized after NMDA treatment.
PROTEASOMES AND NEURONAL MAINTENANCE
Unlike yeast and other mitotic cells, neurons cannot dispose of 
damaged proteins by cell division (Aguilaniu et al., 2003). Hence, 
neuronal proteasomes and their interacting proteins must play 
important roles in clearing abnormal proteins.
The hallmarks of many neurodegenerative disorders are neuronal 
aggregates of misfolded proteins, which often contain ubiquitylated 
proteins and proteasomes (Ross and Poirier, 2004; Rubinsztein, 
2006). It is clearly important to identify the factors that help deliver 
ubiquitylated proteins to proteasomes in neurons, because they 
may be critical in preventing aggregate formation (Chung et al., 
2001; Bedford et al., 2008b; Tai and Schuman, 2008). It is now clear 
that many ubiquitin conjugates (e.g. misfolded proteins degraded 
by the ER-associated degradation pathway or oxidatively damaged 
proteins in yeast) bind ﬁ  rst to the VCP/p97 ATPase complex and 
then are delivered to the 26S complex bound to UBL-proteins (e.g. 
Rad23 or ubiquilin) (Madura, 2004; Medicherla and Goldberg, 2008; 
Nakatsukasa et al., 2008; Finley, 2009). Our data show that p62 and 
the VCP ATPase complex, both of which bind ubiquitylated proteins 
and assist degradation (Dreveny et al., 2004; Seibenhener et al., 2004), 
are associated with neuronal proteasomes. It is attractive to conclude 
that p62 and VCP/p97 function together with UBL-proteins to han-
dle various ubiquitylated substrates at neuronal 26S proteasomes.
Interestingly, genetic studies have shown that the disruption of 
p62 (Ramesh Babu et al., 2008), VCP (Watts et al., 2004; Neumann 
et al., 2007), and 19S particle (Bedford et al., 2008a) in the brain 
leads to ubiquitylated inclusions of tau, TAR-DNA binding protein 
(TDP-43), and α-synuclein, respectively. In fact, these three types 
of inclusions are associated with over 80% of sporadic demen-
tias in humans (Cummings, 2004; Bugiani, 2007), which include 
Alzheimer’s disease (tau), dementia with Lewy bodies (α-synuclein), 
and certain types of frontotemporal dementias (tau or TDP-43). 
Therefore, protein aggregates found in sporadic dementias may 
reﬂ  ect the impairment of different aspects of 26S proteasome func-
tion or substrate delivery to it. Severe 26S dysfunction may also 
contribute to the co-morbidity observed in some dementia cases, 
characterized by multiple aggregate types (for example, α-synu-
clein plus TDP-43) (Nakashima-Yasuda et al., 2007; Kovacs et al., 
2008). Testing these hypotheses in humans or animals has proven 
difﬁ  cult (Lansbury and Lashuel, 2006) in the past due to difﬁ  cul-
ties in isolation of 26S proteasome in its native forms. The afﬁ  nity 
puriﬁ  cation methods used here should greatly facilitate such studies 
of 26S proteasome function in neurodegenerative disorders, studies 
of how neuronal activity regulates 26S proteasome properties, or 
the reported progressive decline of proteasome activity with aging 
(Dahlmann, 2007; Tonoki et al., 2009).
In summary, we found that neuronal proteasomes have a large set 
of interacting proteins that differs from the set of interacting pro-
teins in muscle (Besche et al., 2009) or yeast (Verma et al., 2000). The 
proteasome complex varies in different subcellular localizations and 
changes its content markedly with neuronal activity. Surprisingly, 
brief activation of NMDA-type glutamate receptors leads to a 
reduced capacity of the ubiquitin proteasome pathway through 
rapid disassembly and degradation of the 26S components. This 
newly discovered level of complexity should be taken into considera-
tion in efforts to understand the molecular mechanisms of synaptic 
plasticity, the selective degradation of misfolded brain proteins, and 
the failure to clear such proteins in neurodegenerative diseases.
ACKNOWLEDGMENTS
We thank Dr. Steven Gygi and Dr. Wilhelm Haas at Harvard Medical 
School for their generous support in mass spectrometric analysis. 
Dr. Sonja Hess and Geoffrey Smith at Caltech Protein Exploration 
Lab also assisted in preliminary mass spectrometric experiments. 
We thank members of the Schuman lab and the Goldberg lab 
for helpful suggestions. Supported by Howard Hughes Medical 
Institute (Erin M. Schuman) and California Tobacco-Related 
Disease Research Program (Hwan-Ching Tai).
REFERENCES
Aakalu, G., Smith, W. B., Nguyen, N., 
Jiang, C., and Schuman, E. M. (2001). 
Dynamic visualization of local protein 
synthesis in hippocampal neurons. 
Neuron 30, 489–502.
Aguilaniu, H., Gustafsson, L., Rigoulet, M., 
and Nystrom, T. (2003). Asymmetric 
inheritance of oxidatively damaged 
proteins during cytokinesis. Science 
299, 1751–1753.
Anderson, C., Crimmins, S., Wilson, J. A., 
Korbel, G. A., Ploegh, H. L., and Wilson, 
S. M. (2005). Loss of Usp14 results in 
reduced levels of ubiquitin in ataxia 
mice. J. Neurochem. 95, 724–731.
Bajorek, M., Finley, D., and Glickman, 
M. H. (2003). Proteasome disassem-
bly and downregulation is correlated 
with viability during stationary phase. 
Curr. Biol. 13, 1140–1144.
Bedford, L., Hay, D., Devoy, A., Paine, 
S., Powe, D. G., Seth, R., Gray, T., 
Topham, I., Fone, K., Rezvani, N., Mee, 
M., Soane, T., Layﬁ  eld, R., Sheppard, 
P. W., Ebendal, T., Usoskin, D., Lowe, 
J., and Mayer, R. J. (2008a). Depletion 
of 26S proteasomes in mouse brain 
neurons causes neurodegeneration 
and Lewy-like inclusions resembling 
human pale bodies. J. Neurosci. 28, 
8189–8198.
Bedford, L., Hay, D., Paine, S., Rezvani, 
N., Mee, M., Lowe, J., and Mayer, 
R. J. (2008b). Is malfunction of the 
ubiquitin proteasome system the 
primary cause of alpha-synuclein-
opathies and other chronic human 
 neurodegenerative  disease?  Biochim. 
Biophys. Acta 1782, 683–690.
Besche, H., Haas, W., Gygi, S., and 
Goldberg, A. (2009). Isolation of 
mammalian 26S proteasomes and 
p97/VCP complexes using the ubiqui-
tin-like domain from HHR23B reveals 
novel proteasome-associated proteins. 
Biochemistry 48, 2538–2549.
Bingol, B., and Schuman, E. M. (2004). 
A proteasome-sensitive   connection 
between PSD-95 and GluR1 endocyto-
sis. Neuropharmacology 47, 755–763.
Bingol, B., and Schuman, E. M. (2005). 
Synaptic protein degradation by the 
ubiquitin proteasome system. Curr. 
Opin. Neurobiol. 15, 536–541.
Bingol, B., and Schuman, E. M. (2006). 
Activity-dependent dynamics and 
sequestration of proteasomes in den-
dritic spines. Nature 441, 1144–1148.
Bingol, B., Wang, C. F., Arnott, D., Cheng, 
D., Peng, J., and Sheng, M. (2010). 
Autophosphorylated CaMKIIα acts 
as a scaffold to recruit proteasomes to 
dendritic spines. Cell 140, 567–578.
Bridges, D., and Moorhead, G. B. (2004). 
14-3-3 proteins: a number of func-
tions for a numbered protein. Sci. 
STKE 2004, re10.
Bugiani, O. (2007). The many ways to 
frontotemporal degeneration and 
beyond. Neurol. Sci. 28, 241–244.
Chen, P. C., Qin, L. N., Li, X. M., Walters, B. 
J., Wilson, J. A., Mei, L., and Wilson, S. 
M. (2009). The proteasome- associated 
deubiquitinating enzyme Usp14 
is essential for the maintenance of Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  17
Tai et al.  Characterization of brain proteasomes
synaptic ubiquitin levels and the 
 development of neuromuscular junc-
tions. J. Neurosci. 29, 10909–10919.
Chung, K. K., Dawson, V. L., and Dawson, 
T. M. (2001). The role of the ubiqui-
tin-proteasomal pathway in Parkinson’s 
disease and other neurodegenerative 
disorders. Trends Neurosci. 24, S7–S14.
Colledge, M., Snyder, E. M., Crozier, R. A., 
Soderling, J. A., Jin, Y. T., Langeberg, L. 
K., Lu, H., Bear, M. F., and Scott, J. D. 
(2003). Ubiquitination regulates PSD-
95 degradation and AMPA receptor sur-
face expression. Neuron 40, 595–607.
Crosas, B., Hanna, J., Kirkpatrick, D. S., 
Zhang, D. P., Tone, Y., Hathaway, N. A., 
Buecker, C., Leggett, D. S., Schmidt, M., 
King, R. W., Gygi, S. P., and Finley, D. 
(2006). Ubiquitin chains are remod-
eled at the proteasome by opposing 
ubiquitin ligase and deubiquitinating 
activities. Cell 127, 1401–1413.
Cuervo, A. M., Palmer, A., Rivett, A. J., and 
Knecht, E. (1995). Degradation of pro-
teasomes by lysosomes in rat liver. Eur. 
J. Biochem. 227, 792–800.
Cummings, J. L. (2004). Dementia with 
Lewy bodies: Molecular pathogen-
esis and implications for classifica-
tion. J. Geriatr. Psychiatry Neurol. 17, 
112–119.
Dahlmann, B. (2007). Role of proteasomes 
in disease. BMC Biochem. 8(Suppl. 1), 
S3–S14.
Davidson, H. T., Xiao, J., Dai, R., and 
Bergson, C. (2009). Calcyon is nec-
essary for activity-dependent AMPA 
receptor internalization and LTD in 
CA1 neurons of hippocampus. Eur. J. 
Neurosci. 29, 42–54.
DeBello, W. M., O’Connor, V., Dresbach, 
T., Whiteheart, S. W., Wang, S. S., 
Schweizer, F. E., Betz, H., Rothman, J. 
E., and Augustine, G. J. (1995). SNAP-
mediated protein-protein interactions 
essential for neurotransmitter release. 
Nature 373, 626–630.
Delgado, J. Y., Coba, M., Anderson, C. N., 
Thompson, K. R., Gray, E. E., Heusner, 
C. L., Martin, K. C., Grant, S. G., and 
O’Dell, T. J. (2007). NMDA receptor 
activation dephosphorylates AMPA 
receptor glutamate receptor 1 subu-
nits at threonine 840. J. Neurosci. 27, 
13210–13221.
DiAntonio, A., and Hicke, L. (2004). 
Ubiquitin-dependent regulation of 
the synapse. Annu. Rev. Neurosci. 27, 
223–246.
Dindot, S. V., Antalffy, B. A., Bhattacharjee, 
M. B., and Beaudet, A. L. (2008). The 
Angelman syndrome ubiquitin ligase 
localizes to the synapse and nucleus, 
and maternal deficiency results in 
abnormal dendritic spine morphol-
ogy. Hum. Mol. Genet. 17, 111–118.
Djakovic, S. N., Schwarz, L. A., Barylko, B., 
Demartino, G. N., and Patrick, G. N. 
(2009). Regulation of the proteasome 
by neuronal activity and CAMKII. J. 
Biol. Chem. 284, 26655–26665.
Dohmen, R. J., London, M. K., Glanemann, 
C., and Ramos, P. C. (2005). “Assays for 
proteasome assembly and maturation,” 
in Methods in Molecular Biology, Vol. 
301, Ubiquitin-Proteasome Protocols. 
eds C. Patterson and D. M. Cyr 
(Totowa, NJ: Humana), 243–254.
Dreveny, I., Pye, V. E., Beuron, F., Briggs, 
L. C., Isaacson, R. L., Matthews, S. J., 
McKeown, C., Yuan, X., Zhang, X., and 
Freemont, P. S. (2004). p97 and close 
encounters of every kind: a brief review. 
Biochem. Soc. Trans. 32, 715–720.
Ehlers, M. D. (2000). Reinsertion or degra-
dation of AMPA receptors determined 
by activity-dependent endocytic sort-
ing. Neuron 28, 511–525.
Ehlers, M. D. (2003). Activity level controls 
postsynaptic composition and signal-
ing via the ubiquitin-proteasome sys-
tem. Nat. Neurosci. 6, 231–242.
Elias, J. E., and Gygi, S. P. (2007). Target-
decoy search strategy for increased 
confidence in large-scale protein 
identiﬁ  cations by mass spectrometry. 
Nat. Methods 4, 207–214.
Finley, D. (2009). Recognition and 
processing of ubiquitin-protein con-
jugates by the proteasome. Annu. Rev. 
Biochem. 78, 477–513.
Fonseca, R., Vabulas, R. M., Hartl, F. 
U., Bonhoeffer, T., and Nagerl, U. V. 
(2006). A balance of protein synthesis 
and proteasome-dependent degrada-
tion determines the maintenance of 
LTP. Neuron 52, 239–245.
Froyen, G., Corbett, M., Vandewalle, J., 
Jarvela, I., Lawrence, O., Meldrum, C., 
Bauters, M., Govaerts, K., Vandeleur, 
L., Van Esch, H., Chelly, J., Sanlaville, 
D., van Bokhoven, H., Ropers, H. H., 
Laumonnier, F., Ranieri, E., Schwartz, 
C. E., Abidi, F., Tarpey, P. S., Futreal, 
P. A., Whibley, A., Raymond, F. L., 
Stratton, M. R., Fryns, J. P., Scott, R., 
Peippo, M., Sipponen, M., Partington, 
M., Mowat, D., Field, M., Hackett, A., 
Marynen, P., Turner, G., and Gecz, J. 
(2008). Submicroscopic duplications 
of the hydroxysteroid dehydrogenase 
HSD17B10 and the E3 ubiquitin ligase 
HUWE1 are associated with mental 
retardation. Am. J. Hum. Genet. 82, 
432–443.
Funakoshi, M., Tomko, R. J. Jr., Kobayashi, 
H., and Hochstrasser, M. (2009). 
Multiple assembly chaperones gov-
ern biogenesis of the proteasome 
regulatory particle base. Cell 137, 
887–899.
Glickman, M. H., and Raveh, D. (2005). 
Proteasome plasticity. FEBS Lett. 579, 
3214–3223.
Goldberg, A. L. (2003). Protein degrada-
tion and protection against misfolded 
or damaged proteins. Nature 426, 
895–899.
Gordon-Weeks, P. R. (1987). “Isolation 
of synaptosomes, growth cones and 
their subcellular components,” in 
Neurochemistry: A Practical Approach. 
eds A. J. Turner and H. S. Bachelard 
(Oxford: IRL), 1–26.
Greer, P. L., Hanayama, R., Bloodgood, 
B. L., Mardinly, A. R., Lipton, D. M., 
Flavell, S. W., Kim, T. K., Grifﬁ  th, E. 
C., Waldon, Z., Maehr, R. Ploegh, H. 
L., Chowdhury, S., Worley, P. F., Steen, 
J., and Greenberg, M. E. (2010). The 
Angelman Syndrome protein Ube3A 
regulates synapse development by 
ubiquitinating arc. Cell 140, 704–716.
Guerrero, C., Tagwerker, C., Kaiser, P., 
and Huang, L. (2006). An integrated 
mass spectrometry-based proteomic 
approach: quantitative analysis of 
tandem afﬁ  nity-puriﬁ  ed in vivo cross-
linked protein complexes (QTAX) to 
decipher the 26 S proteasome-inter-
acting network. Mol. Cell Proteomics 
5, 366–378.
Guo, L., and Wang, Y. (2007). Glutamate 
stimulates glutamate receptor inter-
acting protein 1 degradation by 
ubiquitin-proteasome system to 
regulate surface expression of GluR2. 
Neuroscience 145, 100–109.
Haas, W., Faherty, B. K., Gerber, S. A., Elias, 
J. E., Beausoleil, S. A., Bakalarski, C. E., 
Li, X., Villen, J., and Gygi, S. P. (2006). 
Optimization and use of peptide mass 
measurement accuracy in shotgun 
proteomics. Mol. Cell Proteomics 5, 
1326–1337.
Hanna, J., and Finley, D. (2007). A protea-
some for all occasions. FEBS Lett. 581, 
2854–2861.
Hershko, A., and Ciechanover, A. (1998). 
The ubiquitin system. Annu. Rev. 
Biochem. 67, 425–479.
Hou, L., Antion, M. D., Hu, D., Spencer, 
C. M., Paylor, R., and Klann, E. (2006). 
Dynamic translational and protea-
somal regulation of fragile X mental 
retardation protein controls mGluR-
dependent long-term depression. 
Neuron 51, 441–454.
Humeau, Y., Gambino, F., Chelly, J., and 
Vitale, N. (2009). X-linked mental 
retardation: focus on synaptic func-
tion and plasticity. J. Neurochem. 109, 
1–14.
Iha, H., Peloponese, J. M., Verstrepen, 
L., Zapart, G., Ikeda, F., Smith, C. D., 
Starost, M. F., Yedavalli, V., Heyninck, 
K., Dikic, I., Beyaert, R., and Jeang, 
K. T. (2008). Inflammatory cardiac 
valvulitis in TAX1BP1-deﬁ  cient mice 
through selective NF-kappaB activa-
tion. EMBO J. 27, 629–641.
Jiang, Y. H., Armstrong, D., Albrecht, U., 
Atkins, C. M., Noebels, J. L., Eichele, G., 
Sweatt, J. D., and Beaudet, A. L. (1998). 
Mutation of the Angelman ubiquitin 
ligase in mice causes increased cyto-
plasmic p53 and deﬁ  cits of contextual 
learning and long-term potentiation. 
Neuron 21, 799–811.
Kaneko, T., Hamazaki, J., Iemura, S., 
Sasaki, K., Furuyama, K., Natsume, 
T., Tanaka, K., and Murata, S. (2009). 
Assembly pathway of the Mammalian 
proteasome base subcomplex is medi-
ated by multiple speciﬁ  c chaperones. 
Cell 137, 914–925.
Karpova, A., Mikhaylova, M., Thomas, U., 
Knopfel, T., and Behnisch, T. (2006). 
Involvement of protein synthesis and 
degradation in long-term potentiation 
of Schaffer collateral CA1 synapses. J. 
Neurosci. 26, 4949–4955.
Kleijnen, M. F., Roelofs, J., Park, S., 
Hathaway, N. A., Glickman, M., King, 
R. W., and Finley, D. (2007). Stability 
of the proteasome can be regulated 
allosterically through engagement of 
its proteolytic active sites. Nat. Struct. 
Mol. Biol. 14, 1180–1188.
Koulich, E., Li, X., and DeMartino, 
G. N. (2008). Relative structural 
and functional roles of multiple 
 deubiquitylating  proteins  associated 
with mammalian 26S proteasome. 
Mol. Biol. Cell 19, 1072–1082.
Kovacs, G. G., Alafuzoff, I., Al-Sarraj, 
S., Arzberger, T., Bogdanovic, N., 
Capellari, S., Ferrer, I., Gelpi, E., 
Kovari, V., Kretzschmar, H., Nagy, Z., 
Parchi, P., Seilhean, D., Soininen, H., 
Troakes, C., and Budka, H. (2008). 
Mixed brain pathologies in demen-
tia: the BrainNet Europe consortium 
experience. Dement. Geriatr. Cogn. 
Disord. 26, 343–350.
Kraut, D. A., Prakash, S., and Matouschek, 
A. (2007). To degrade or release: ubiq-
uitin-chain remodeling. Trends Cell 
Biol. 17, 419–421.
Kriegenburg, F., Seeger, M., Saeki, 
Y., Tanaka, K., Lauridsen, A. M., 
Hartmann-Petersen, R., and Hendil, 
K. B. (2008). Mammalian 26S protea-
somes remain intact during protein 
degradation. Cell 135, 355–365.
Krogan, N. J., Lam, M. H., Fillingham, 
J., Keogh, M. C., Gebbia, M., Li, J., 
Datta, N., Cagney, G., Buratowski, S., 
Emili, A., and Greenblatt, J. F. (2004). 
Proteasome involvement in the repair 
of DNA double-strand breaks. Mol. 
Cell. 16, 1027–1034.
Lalande, M., and Calciano, M. A. (2007). 
Molecular epigenetics of Angelman 
syndrome. Cell. Mol. Life Sci. 64, 
947–960.
Lansbury, P. T., and Lashuel, H. A. (2006). 
A century-old debate on protein aggre-
gation and neurodegeneration enters 
the clinic. Nature 443, 774–779.
Lee, H. K., Kameyama, K., Huganir, R. 
L., and Bear, M. F. (1998). NMDA Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  18
Tai et al.  Characterization of brain proteasomes
induces long-term synaptic depression 
and dephosphorylation of the GluR1 
subunit of AMPA receptors in hippoc-
ampus. Neuron 21, 1151–1162.
Lee, S. H., Choi, J. H., Lee, N., Lee, H. R., 
Kim, J. I., Yu, N. K., Choi, S. L., Kim, 
H., and Kaang, B. K. (2008). Synaptic 
protein degradation underlies desta-
bilization of retrieved fear memory. 
Science 319, 1253–1256.
Lee, S. H., Simonetta, A., and Sheng, M. 
(2004). Subunit rules governing the 
sorting of internalized AMPA recep-
tors in hippocampal neurons. Neuron 
43, 221–236.
Leggett, D. S., Hanna, J., Borodovsky, A., 
Crosas, B., Schmidt, M., Baker, R. T., 
Walz, T., Ploegh, H., and Finley, D. 
(2002). Multiple associated proteins 
regulate proteasome structure and 
function. Mol. Cell 10, 495–507.
Le Tallec, B., Barrault, M. B., Guerois, R., 
Carre, T., and Peyroche, A. (2009). 
Hsm3/S5b participates in the assem-
bly pathway of the 19S regulatory 
particle of the proteasome. Mol. Cell 
33, 389–399.
Li, R., Dozmorov, M., Hellberg, F., Tian, 
Y., Jilderos, B., and Wigstrom, H. 
(2004). Characterization of NMDA 
induced depression in rat hippoc-
ampus: involvement of AMPA and 
NMDA receptors. Neurosci. Lett. 
357, 87–90.
Li, X., Lonard, D. M., Jung, S. Y., 
Malovannaya, A., Feng, Q., Qin, J., 
Tsai, S. Y., Tsai, M. J., and O’Malley, B. W. 
(2006). The SRC-3/AIB1 coactivator is 
degraded in a ubiquitin- and ATP-inde-
pendent manner by the REGgamma 
proteasome. Cell 124, 381–392.
Lopez-Salon, M., Alonso, M., Vianna, 
M. R. M., Viola, H., Souza, T. M. E., 
Izquierdo, I., Pasquini, J. M., and 
Medina, J. H. (2001). The ubiqui-
tin-proteasome cascade is required 
for mammalian long-term memory 
formation.  Eur. J. Neurosci. 14, 
1820–1826.
Lu, W., and Ziff, E. B. (2005). PICK1 
interacts with ABP/GRIP to regulate 
AMPA receptor trafﬁ  cking. Neuron 
47, 407–421.
Madura, K. (2004). Rad23 and Rpn10: 
perennial wallﬂ  owers join the melee. 
Trends Biochem. Sci. 29, 637–640.
Malenka, R. C., and Bear, M. F. (2004). 
LTP and LTD: an embarrassment of 
riches. Neuron 44, 5–21.
McCutchen-Maloney, S. L., Matsuda, K., 
Shimbara, N., Binns, D. D., Tanaka, K., 
Slaughter, C. A., and DeMartino, G. N. 
(2000). cDNA cloning, expression, and 
functional characterization of PI31, a 
proline-rich inhibitor of the proteas-
ome. J. Biol. Chem. 275, 18557–18565.
Medicherla, B., and Goldberg, A. L. (2008). 
Heat shock and oxygen radicals stimu-
late ubiquitin-dependent degradation 
mainly of newly synthesized proteins. 
J. Cell Biol. 182, 663–673.
Mitch, W. E., and Goldberg, A. L. (1996). 
Mechanisms of muscle wasting. The 
role of the ubiquitin-proteasome path-
way. N. Engl. J. Med. 335, 1897–1905.
Montecucco, C., Schiavo, G., and Pantano, 
S. (2005). SNARE complexes and neu-
roexocytosis: how many, how close? 
Trends Biochem. Sci. 30, 367–372.
Nakashima-Yasuda, H., Uryu, K., 
Robinson, J., Xie, S. X., Hurtig, H., 
Duda, J. E., Arnold, S. E., Siderowf, A., 
Grossman, M., Leverenz, J. B., Woltjer, 
R., Lopez, O. L., Hamilton, R., Tsuang, 
D. W., Galasko, D., Masliah, E., Kaye, 
J., Clark, C. M., Montine, T. J., Lee, V. 
M., and Trojanowski, J. Q. (2007). Co-
morbidity of TDP-43 proteinopathy 
in Lewy body related diseases. Acta 
Neuropathol. 114, 221–229.
Nakatsukasa, K., Huyer, G., Michaelis, S., 
and Brodsky, J. L. (2008). Dissecting 
the ER-associated degradation of a 
misfolded polytopic membrane pro-
tein. Cell 132, 101–112.
Neumann, M., Mackenzie, I. R., Cairns, 
N. J., Boyer, P. J., Markesbery, W. R., 
Smith, C. D., Taylor, J. P., Kretzschmar, 
H. A., Kimonis, V. E., and Forman, 
M. S. (2007). TDP-43 in the ubiq-
uitin pathology of frontotemporal 
dementia with VCP gene mutations. 
J. Neuropathol. Exp. Neurol. 66, 
152–157.
Park, S., Roelofs, J., Kim, W., Robert, J., 
Schmidt, M., Gygi, S. P., and Finley, D. 
(2009). Hexameric assembly of the pro-
teasomal ATPases is templated through 
their C termini. Nature 459, 866–870.
Patrick, G. N., Bingol, B., Weld, H. A., and 
Schuman, E. M. (2003). Ubiquitin-
mediated proteasome activity is 
required for agonist-induced endo-
cytosis of GluRs. Curr. Biol. 13, 
2073–2081.
Peth, A., Besche, H. C., and Goldberg, 
A. L. (2009). Ubiquitinated proteins 
activate the proteasome by binding to 
Usp14/Ubp6, which causes 20S gate 
opening. Mol. Cell 36, 794–804.
Poppek, D., and Grune, T. (2006). 
Proteasomal defense of oxidative 
protein modiﬁ  cations. Antioxid. Redox 
Signal. 8, 173–184.
Ramesh Babu, J., Lamar Seibenhener, M., 
Peng, J., Strom, A. L., Kemppainen, 
R., Cox, N., Zhu, H., Wooten, M. C., 
Diaz-Meco, M. T., Moscat, J., and 
Wooten, M. W. (2008). Genetic inac-
tivation of p62 leads to accumulation 
of hyperphosphorylated tau and neu-
rodegeneration. J. Neurochem. 106, 
107–120.
Rechsteiner, M., and Hill, C. P. (2005). 
Mobilizing the proteolytic machine: 
cell biological roles of proteasome 
activators and inhibitors. Trends Cell 
Biol. 15, 27–33.
Roelofs, J., Park, S., Haas, W., Tian, G., 
McAllister, F. E., Huo, Y., Lee, B.-H., 
Zhang, F., Shi, Y., Gygi, S. P., and Finley, 
D. (2009). Chaperone-mediated path-
way of proteasome regulatory particle 
assembly. Nature 459, 861–865.
Ross, C. A., and Poirier, M. A. (2004). 
Protein aggregation and neurode-
generative disease. Nat. Med. 10, 
S10–S17.
Rubinsztein, D. C. (2006). The roles of 
intracellular protein-degradation 
pathways in neurodegeneration. 
Nature 443, 780–786.
Saeki, Y., Toh, E. A., Kudo, T., Kawamura, 
H., and Tanaka, K. (2009). Multiple 
Proteasome-interacting proteins assist 
the assembly of the yeast 19S regula-
tory particle. Cell 137, 900–913.
Sakata, E., Yamaguchi, Y., Kurimoto, E., 
Kikuchi, J., Yokoyama, S., Yamada, S., 
Kawahara, H., Yokosawa, H., Hattori, 
N., Mizuno, Y., Tanaka, K., and Kato, 
K. (2003). Parkin binds the Rpn10 
subunit of 26S proteasomes through 
its ubiquitin-like domain. EMBO Rep. 
4, 301–306.
Scanlon, T. C., Gottlieb, B., Durcan, T. M., 
Fon, E. A., Beitel, L. K., and Triﬁ  ro, M. 
A. (2009). Isolation of human protea-
somes and putative proteasome-inter-
acting proteins using a novel afﬁ  nity 
chromatography method. Exp. Cell 
Res. 315, 176–189.
Schauber, C., Chen, L., Tongaonkar, P., 
Vega, I., Lambertson, D., Potts, W., and 
Madura, K. (1998). Rad23 links DNA 
repair to the ubiquitin/proteasome 
pathway. Nature 391, 715–718.
Schmidt, M., Hanna, J., Elsasser, S., and 
Finley, D. (2005). Proteasome-associ-
ated proteins: regulation of a proteolytic 
machine. Biol. Chem. 386, 725–737.
Seibenhener, M. L., Babu, J. R., Geetha, 
T., Wong, H. C., Krishna, N. R., and 
Wooten, M. W. (2004). Sequestosome 
1/p62 is a polyubiquitin chain binding 
protein involved in ubiquitin protea-
some degradation. Mol. Cell. Biol. 24, 
8055–8068.
Semple, C. A. M. (2003). The compara-
tive proteomics of ubiquitination in 
mouse. Genome Res. 13, 1389–1394.
Shembade, N., Harhaj, N. S., Parvatiyar, 
K., Copeland, N. G., Jenkins, N. A., 
Matesic, L. E., and Harhaj, E. W. 
(2008). The E3 ligase Itch negatively 
regulates inflammatory signaling 
pathways by controlling the function 
of the ubiquitin-editing enzyme A20. 
Nat. Immunol. 9, 254–262.
Sherman, M. Y., and Goldberg, A. L. 
(2001). Cellular defenses against 
unfolded proteins: a cell biologist 
thinks about neurodegenerative dis-
eases. Neuron 29, 15–32.
Smith, D. M., Chang, S. C., Park, S., Finley, 
D., Cheng, Y., and Goldberg, A. L. 
(2007). Docking of the proteasomal 
ATPases’ carboxyl termini in the 20S 
proteasome’s alpha ring opens the 
gate for substrate entry. Mol. Cell 27, 
731–744.
Tai, H. C., and Schuman, E. M. (2008). 
Ubiquitin, the proteasome and pro-
tein degradation in neuronal function 
and dysfunction. Nat. Rev. Neurosci. 
9, 826–838.
Takahashi, H., Yamazaki, H., Hanamura, 
K., Sekino, Y., and Shirao, T. (2009). 
Activity of the AMPA receptor regu-
lates drebrin stabilization in dendritic 
spine morphogenesis. J. Cell. Sci. 122, 
1211–1219.
Tanaka, K. (2009). The proteasome: over-
view of structure and functions. Proc. 
Jpn. Acad., Ser. B, Phys. Biol. Sci. 85, 
12–36.
Tonoki, A., Kuranaga, E., Tomioka, T., 
Hamazaki, J., Murata, S., Tanaka, K., 
and Miura, M. (2009). Genetic evi-
dence linking age-dependent attenu-
ation of the 26S proteasome with 
the aging process. Mol. Cell. Biol. 29, 
1095–1106.
Tsvetkov, P., Reuven, N., and Shaul, Y. 
(2009). The nanny model for IDPs. 
Nat. Chem. Biol. 5, 778–781.
Verma, R., Chen, S., Feldman, R., Schieltz, 
D., Yates, J., Dohmen, T., and Deshaies, 
R. J. (2000). Proteasomal proteomics: 
Identiﬁ  cation of nucleotide-sensitive 
proteasome-interacting proteins by 
mass spectrometric analysis of afﬁ  n-
ity-puriﬁ  ed proteasomes. Mol. Biol. 
Cell 11, 3425–3439.
Wang, X. R., Chen, C. F., Baker, P. R., Chen, 
P. L., Kaiser, P., and Huang, L. (2007). 
Mass spectrometric characterization 
of the affinity-purified human 26S 
proteasome complex. Biochemistry 
46, 3553–3565.
Wang, X. R., and Huang, L. (2008). 
Identifying dynamic interactors 
of protein complexes by quantita-
tive mass spectrometry. Mol. Cell 
Proteomics 7, 46–57.
Watts, G. D., Wymer, J., Kovach, M. J., 
Mehta, S. G., Mumm, S., Darvish, 
D., Pestronk, A., Whyte, M. P., and 
Kimonis, V. E. (2004). Inclusion body 
myopathy associated with Paget dis-
ease of bone and frontotemporal 
dementia is caused by mutant val-
osin-containing protein. Nat. Genet. 
36, 377–381.
Willeumier, K., Pulst, S. M., and Schweizer, 
F. E. (2006). Proteasome inhibition 
triggers activity-dependent increase 
in the size of the recycling vesicle pool 
in cultured hippocampal neurons. J. 
Neurosci. 26, 11333–11341.
Wilson, S. M., Bhattacharyya, B., Rachel, 
R. A., Coppola, V., Tessarollo, L., Frontiers in Molecular Neuroscience  www.frontiersin.org  May 2010  | Volume 3  |  Article 12  |  19
Tai et al.  Characterization of brain proteasomes
Householder, D. B., Fletcher, C. F., 
Miller, R. J., Copeland, N. G., and 
Jenkins, N. A. (2002). Synaptic defects 
in ataxia mice result from a mutation in 
Usp14, encoding a ubiquitin-speciﬁ  c 
protease. Nat. Genet. 32, 420–425.
Yao, I., Takagi, H., Ageta, H., Kahyo, 
T., Sato, S., Hatanaka, K., Fukuda, 
Y., Chiba, T., Morone, N., Yuasa, S. 
Inokuchi, K., Ohtsuka, T., MacGregor, 
G. R., Tanaka, K., and Setou, M. (2007). 
SCRAPPER-dependent ubiquitina-
tion of active zone protein RIM1 
regulates synaptic vesicle release. Cell 
130, 943–957.
Yi, J. J., and Ehlers, M. D. (2007). Emerging 
roles for ubiquitin and protein deg-
radation in neuronal function. 
Pharmacol. Rev. 59, 14–39.
Conflict of Interest Statement: The 
authors declare that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential conﬂ  ict 
of interest.
Received: 04 December 2009; paper pend-
ing published: 26 February 2010; accepted: 
21 April 2010; published online: 21 May 
2010.
Citation: Tai H-C, Besche H, Goldberg AL 
and Schuman EM (2010) Characterization 
of the brain 26S proteasome and its interact-
ing proteins. Front. Mol. Neurosci. 3:12. doi: 
10.3389/fnmol.2010.00012
Copyright © 2010 Tai, Besche, Goldberg 
and Schuman. This is an open-access arti-
cle subject to an exclusive license agreement 
between the authors and the Frontiers 
Research Foundation, which permits unre-
stricted use, distribution, and reproduc-
tion in any medium, provided the original 
authors and source are credited.